Document:

<PAGE>

                                  EXHIBIT 10.22

                              THEHEALTHCHANNEL.COM

                              INVESTMENT AGREEMENT

                             Dated: August 15, 2000

<PAGE>

                              THEHEALTHCHANNEL.COM

                              INVESTMENT AGREEMENT

         THE SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED WITH THE
         SECURITIES AND EXCHANGE COMMISSION OR ANY STATE OR OTHER SECURITIES
         AUTHORITIES. THEY MAY NOT BE SOLD OR TRANSFERRED EXCEPT PURSUANT TO AN
         EFFECTIVE REGISTRATION STATEMENT OR AN EXEMPTION FROM THE REGISTRATION
         REQUIREMENTS OF THE FEDERAL AND STATE SECURITIES LAWS.

         THIS INVESTMENT AGREEMENT DOES NOT CONSTITUTE AN OFFER TO SELL, OR A
         SOLICITATION OF AN OFFER TO PURCHASE, ANY OF THE SECURITIES DESCRIBED
         HEREIN BY OR TO ANY PERSON IN ANY JURISDICTION IN WHICH SUCH OFFER OR
         SOLICITATION WOULD BE UNLAWFUL. THESE SECURITIES HAVE NOT BEEN
         RECOMMENDED BY ANY FEDERAL OR STATE SECURITIES AUTHORITIES, NOR HAVE
         SUCH AUTHORITIES CONFIRMED THE ACCURACY OR DETERMINED THE ADEQUACY OF
         THIS DOCUMENT. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL
         OFFENSE.

         AN INVESTMENT IN THESE SECURITIES INVOLVES A HIGH DEGREE OF RISK. THE
         INVESTOR MUST RELY ON ITS OWN ANALYSIS OF THE INVESTMENT AND ASSESSMENT
         OF THE RISKS INVOLVED. SEE THE RISK FACTORS SET FORTH IN THE ATTACHED
         DISCLOSURE DOCUMENTS AS EXHIBIT J.

         SEE ADDITIONAL LEGENDS AT SECTIONS 4.7.

                  THIS INVESTMENT AGREEMENT (this "Agreement" or "Investment
Agreement") is made as of the 15th day of August, 2000, by and between
thehealthchannel.com, a corporation duly organized and existing under the laws
of the State of Delaware (the "Company"), and the undersigned Investor executing
this Agreement ("Investor").

                                    RECITALS:

         WHEREAS, the parties desire that, upon the terms and subject to the
conditions contained herein, the Company shall issue to the Investor, and the
Investor shall purchase from the Company, from time to time as provided herein,
shares of the Company's Common Stock, as part of an offering of Common Stock by
the Company to Investor, for a maximum aggregate offering amount of Thirty
Million Dollars ($30,000,000) (the "Maximum Offering Amount"); and

         WHEREAS, the solicitation of this Investment Agreement and, if accepted
by the Company, the offer and sale of the Common Stock are being made in
reliance upon the provisions of Regulation D ("Regulation D") promulgated under
the Act, Section 4(2) of the Act, and/or upon such other exemption from the
registration requirements of the Act as may be available with respect to any or
all of the purchases of Common Stock to be made hereunder.

                                     TERMS:

         NOW, THEREFORE, the parties hereto agree as follows:

         1. CERTAIN DEFINITIONS. As used in this Agreement (including the
recitals above), the following terms shall have the following meanings (such
meanings to be equally applicable to both the singular and plural forms of the
terms defined):

<PAGE>

         "20% Approval" shall have the meaning set forth in Section 5.25.

         "9.9% Limitation" shall have the meaning set forth in Section 2.3.1(f).

         "Accredited Investor" shall have the meaning set forth in Section 3.1.

         "Act" shall mean the Securities Act of 1933, as amended.

         "Advance Put Notice" shall have the meaning set forth in Section
2.3.1(a), the form of which is attached hereto as EXHIBIT E.

         "Advance Put Notice Confirmation" shall have the meaning set forth in
Section 2.3.1(a), the form of which is attached hereto as EXHIBIT F.

         "Advance Put Notice Date" shall have the meaning set forth in Section
2.3.1(a).

         "Affiliate" shall have the meaning as set forth Section 6.4.

         "Aggregate Issued Shares" equals the aggregate number of shares of
Common Stock issued to Investor pursuant to the terms of this Agreement or the
Registration Rights Agreement as of a given date, including Put Shares and
Warrant Shares.

         "Agreed Upon Procedures Report" shall have the meaning set forth in
Section 2.5.3(b).

         "Agreement" shall mean this Investment Agreement.

         "Automatic Termination" shall have the meaning set forth in Section
2.3.2.

         "Bring Down Cold Comfort Letters" shall have the meaning set forth in
Section 2.3.6(b).

         "Business Day" shall mean any day during which the Principal Market is
open for trading.

         "Calendar Month" shall mean the period of time beginning on the numeric
day in question in a calendar month and for Calendar Months thereafter,
beginning on the earlier of (i) the same numeric day of the next calendar month
or (ii) the last day of the next calendar month. Each Calendar Month shall end
on the day immediately preceding the beginning of the next succeeding Calendar
Month.

         "Cap Amount" shall have the meaning set forth in Section 2.3.10.

         "Capital Raising Limitations" shall have the meaning set forth in
Section 6.5.1.

         "Capitalization Schedule" shall have the meaning set forth in Section
3.2.4, attached hereto as EXHIBIT K.

         "Closing" shall mean one of (i) the Investment Commitment Closing and
(ii) each closing of a purchase and sale of Common Stock pursuant to Section 2.

         "Closing Bid Price" means, for any security as of any date, the last
closing bid price for such security during Normal Trading on the O.T.C. Bulletin
Board, or, if the O.T.C. Bulletin Board is not the principal securities exchange
or trading market for such security, the last closing bid price during Normal
Trading of such security on the principal securities exchange or trading market
where such security is listed or traded as reported by such principal securities
exchange or trading market, or if the foregoing do not apply, the last closing
bid price during Normal Trading of such security in the over-the-counter market
on the electronic bulletin board for such security, or, if no closing bid price
is reported for such security, the average of the bid prices of any market
makers for such security as reported in the "pink sheets" by the National
Quotation Bureau, Inc. If the Closing Bid Price cannot be calculated for such
security on such date on any of the foregoing bases, the Closing Bid Price of
such security on such date shall be the fair market value as mutually determined
by the Company and the Investor in this Offering. If

<PAGE>

the Company and the Investor in this Offering are unable to agree upon the
fair market value of the Common Stock, then such dispute shall be resolved by
an investment banking firm mutually acceptable to the Company and the
Investor in this offering and any fees and costs associated therewith shall
be paid by the Company.

         "Commitment Evaluation Period" shall have the meaning set forth in
Section 2.6.

         "Commitment Warrants" shall have the meaning set forth in Section
2.4.1, the form of which is attached hereto as EXHIBIT U.

         "Commitment Warrant Exercise Price" shall have the meaning set forth in
Section 2.4.1.

         "Common Shares" shall mean the shares of Common Stock of the Company.

         "Common Stock" shall mean the common stock of the Company.

         "Company" shall mean thehealthchannel.com, a corporation duly organized
and existing under the laws of the State of Delaware.

         "Company Designated Maximum Put Dollar Amount" shall have the meaning
set forth in Section 2.3.1(a).

         "Company Designated Minimum Put Share Price" shall have the meaning set
forth in Section 2.3.1(a).

         "Company Termination" shall have the meaning set forth in
Section 2.3.12.

         "Conditions to Investor's Obligations" shall have the meaning as set
forth in Section 2.2.2.

          "Delisting Event" shall mean any time during the term of this
Investment Agreement, that the Company's Common Stock is not listed for and
actively trading on the O.T.C. Bulletin Board, the Nasdaq Small Cap Market, the
Nasdaq National Market, the American Stock Exchange, or the New York Stock
Exchange or is suspended or delisted with respect to the trading of the shares
of Common Stock on such market or exchange.

         "Disclosure Documents" shall have the meaning as set forth in Section
3.2.4.

         "Due Diligence Review" shall have the meaning as set forth in Section
2.5.

         "Effective Date" shall have the meaning set forth in Section 2.3.1.

         "Equity Securities" shall have the meaning set forth in Section 6.5.1.

         "Evaluation Day" shall have the meaning set forth in Section 2.3.1(b).

         "Exchange Act" shall mean the Securities Exchange Act of 1934, as
amended.

         "Excluded Day" shall have the meaning set forth in Section 2.3.1(b).

         "Extended Put Period" shall mean the period of time between the Advance
Put Notice Date until the Pricing Period End Date.

         "Impermissible Put Cancellation" shall have the meaning set forth in
Section 2.3.1(e).

         "Indemnified Liabilities" shall have the meaning set forth in Section
9.

         "Indemnities" shall have the meaning set forth in Section 9.

         "Indemnitor" shall have the meaning set forth in Section 9.

<PAGE>

         "Individual Put Limit" shall have the meaning set forth in Section
2.3.1 (b).

          "Ineffective Period" shall mean any period of time that the
Registration Statement or any Supplemental Registration Statement (each as
defined in the Registration Rights Agreement) becomes ineffective or unavailable
for use for the sale or resale, as applicable, of any or all of the Registrable
Securities (as defined in the Registration Rights Agreement) for any reason (or
in the event the prospectus under either of the above is not current and
deliverable) during any time period required under the Registration Rights
Agreement.

         "Intended Put Share Amount" shall have the meaning set forth in Section
2.3.1(a).

         "Investment Commitment Closing" shall have the meaning set forth in
Section 2.2.1.

         "Investment Agreement" shall mean this Investment Agreement.

         "Investment Commitment Opinion of Counsel" shall mean an opinion from
Company's independent counsel, substantially in the form attached as EXHIBIT B,
or such other form as agreed upon by the parties, as to the Investment
Commitment Closing.

         "Investment Date" shall mean the date of the Investment Commitment
Closing.

         "Investor" shall have the meaning set forth in the preamble hereto.

         "Key Employee" shall have the meaning set forth in Section 5.17, as set
forth in EXHIBIT N.

         "Late Payment Amount" shall have the meaning set forth in Section
2.3.8.

         "Legend" shall have the meaning set forth in Section 4.7.

         "Major Transaction" shall mean and shall be deemed to have occurred at
such time upon any of the following events:

                  (i) a consolidation, merger or other business combination or
event or transaction following which the holders of Common Stock of the Company
immediately preceding such consolidation, merger, combination or event either
(i) no longer hold a majority of the shares of Common Stock of the Company or
(ii) no longer have the ability to elect the board of directors of the Company
(a "Change of Control"); provided, however, that if the other entity involved in
such consolidation, merger, combination or event is a publicly traded company
with "Substantially Similar Trading Characteristics" (as defined below) as the
Company and the holders of Common Stock are to receive solely Common Stock or no
consideration (if the Company is the surviving entity) or solely common stock of
such other entity (if such other entity is the surviving entity), such
transaction shall not be deemed to be a Major Transaction (provided the
surviving entity, if other than the Company, shall have agreed to assume all
obligations of the Company under this Agreement and the Registration Rights
Agreement). For purposes hereof, an entity shall have Substantially Similar
Trading Characteristics as the Company if the average daily dollar Trading
Volume of the common stock of such entity is equal to or in excess of $500,000
for the 90th through the 31st day prior to the public announcement of such
transaction;

                  (ii) the sale or transfer of all or substantially all of the
Company's assets; or

                  (iii) a purchase, tender or exchange offer made to the holders
of outstanding shares of Common Stock, such that following such purchase, tender
or exchange offer a Change of Control shall have occurred.

         "Market Price" shall equal the lowest Closing Bid Price for the Common
Stock on the Principal Market during the Pricing Period for the applicable Put.

         "Material Facts" shall have the meaning set forth in Section 2.3.6(a).

<PAGE>

         "Maximum Put Dollar Amount" shall mean the lesser of (i) the Company
Designated Maximum Put Dollar Amount, if any, specified by the Company in a Put
Notice, and (ii) $2 million.

         "Maximum Offering Amount" shall mean have the meaning set forth in the
recitals hereto.

         "NASD" shall have the meaning set forth in Section 6.9.

         "Nasdaq 20% Rule" shall have the meaning set forth in Section 2.3.10.

         "Normal Trading" shall mean trading that occurs between 9:30 AM and
4:00 PM, New York City Time, on any Business Day, and shall expressly exclude
"after hours" trading.

         "Numeric Day" shall mean the numerical day of the month of the
Investment Date or the last day of the calendar month in question, whichever is
less.

         "NYSE" shall have the meaning set forth in Section 6.9.

         "Offering" shall mean the Company's offering of Common Stock and
Warrants issued under this Investment Agreement.

         "Officer's Certificate" shall mean a certificate, signed by an officer
of the Company, to the effect that the representations and warranties of the
Company in this Agreement required to be true for the applicable Closing are
true and correct in all material respects and all of the conditions and
limitations set forth in this Agreement for the applicable Closing are
satisfied.

         "Opinion of Counsel" shall mean, as applicable, the Investment
Commitment Opinion of Counsel, the Put Opinion of Counsel, and the Registration
Opinion.

         "Payment Due Date" shall have the meaning set forth in Section 2.3.8.

         "Pricing Period" shall mean, unless otherwise shortened under the terms
of this Agreement, the period beginning on the Business Day immediately
following the Put Date and ending on and including the date which is 20 Business
Days after such Put Date.

         "Pricing Period End Date" shall mean the last Business Day of any
Pricing Period.

         "Principal Market" shall mean the O.T.C. Bulletin Board, the Nasdaq
Small Cap Market, the Nasdaq National Market, the American Stock Exchange or the
New York Stock Exchange, whichever is at the time the principal trading exchange
or market for the Common Stock.

         "Proceeding" shall have the meaning as set forth Section 5.1.

         "Purchase" shall have the meaning set forth in Section 2.3.7.

         "Purchase Warrant Exercise Price" shall have the meaning set forth in
Section 2.4.2.

         "Purchase Warrants" shall have the meaning set forth in Section 2.4.2,
the form of which is attached hereto as EXHIBIT D.

         "Put" shall have the meaning set forth in Section 2.3.1(d).

         "Put Cancellation" shall have the meaning set forth in
Section 2.3.11(a).

         "Put Cancellation Date" shall have the meaning set forth in Section
2.3.11(a).

<PAGE>

         "Put Cancellation Notice" shall have the meaning set forth in Section
2.3.11(a), the form of which is attached hereto as EXHIBIT Q.

         "Put Cancellation Notice Confirmation" shall have the meaning set forth
in Section 2.3.11(c), the form of which is attached hereto as EXHIBIT S.

         "Put Closing" shall have the meaning set forth in Section 2.3.8.

         "Put Closing Date" shall have the meaning set forth in Section 2.3.8.

         "Put Date" shall mean the date that is specified by the Company in any
Put Notice for which the Company intends to exercise a Put under Section 2.3.1,
unless the Put Date is postponed pursuant to the terms hereof, in which case the
"Put Date" is such postponed date.

         "Put Dollar Amount" shall be determined by multiplying the Put Share
Amount by the respective Put Share Prices with respect to such Put Shares,
subject to the limitations herein.

         "Put Notice" shall have the meaning set forth in Section 2.3.1(d), the
form of which is attached hereto as EXHIBIT G.

         "Put Notice Confirmation" shall have the meaning set forth in Section
2.3.1(d), the form of which is attached hereto as EXHIBIT H.

         "Put Opinion of Counsel" shall mean an opinion from Company's
independent counsel, in the form attached as EXHIBIT I, or such other form as
agreed upon by the parties, as to any Put Closing.

         "Put Share Amount" shall have the meaning as set forth Section
2.3.1(b).

         "Put Share Price" shall have the meaning set forth in Section 2.3.1(c).

         "Put Shares" shall mean shares of Common Stock that are purchased by
the Investor pursuant to a Put.

         "Registrable Securities" shall have the meaning as set forth in the
Registration Rights Agreement.

         "Registration Opinion" shall have the meaning set forth in Section
2.3.6(a), the form of which is attached hereto as EXHIBIT R.

         "Registration Opinion Deadline" shall have the meaning set forth in
Section 2.3.6(a).

         "Registration Rights Agreement" shall mean that certain registration
rights agreement entered into by the Company and Investor on even date herewith,
in the form attached hereto as EXHIBIT A, or such other form as agreed upon by
the parties.

         "Registration Statement" shall have the meaning as set forth in the
Registration Rights Agreement.

         "Regulation D" shall have the meaning set forth in the recitals hereto.

         "Reporting Issuer" shall have the meaning set forth in Section 6.2.

         "Restrictive Legend" shall have the meaning set forth in Section 4.7.

         "Required Put Documents" shall have the meaning set forth in Section
2.3.5.

         "Right of First Refusal" shall have the meaning set forth in Section
6.5.2.

         "Risk Factors" shall have the meaning set forth in Section 3.2.4,
attached hereto as EXHIBIT J.

<PAGE>

         "Schedule of Exceptions" shall have the meaning set forth in Section 5,
and is attached hereto as Exhibit C.

         "SEC" shall mean the Securities and Exchange Commission.

         "Securities" shall mean this Investment Agreement, together with the
Common Stock of the Company, the Warrants and the Warrant Shares issuable
pursuant to this Investment Agreement.

         "Semi-Annual Non-Usage Fee" shall have the meaning set forth in Section
2.6.

         "Share Authorization Increase Approval" shall have the meaning set
forth in Section 5.25.

         "Stockholder 20% Approval" shall have the meaning set forth in Section
6.11.

         "Supplemental Registration Statement" shall have the meaning set forth
in the Registration Rights Agreement.

         "Term" shall mean the term of this Agreement, which shall be a period
of time beginning on the date of this Agreement and ending on the Termination
Date.

         "Termination Date" shall mean the earlier of (i) the date that is three
(3) years after the Effective Date, or (ii) the date that is thirty (30)
Business Days after the later of (a) the Put Closing Date on which the sum of
the aggregate Put Share Price for all Put Shares equal the Maximum Offering
Amount, (b) the date that the Company has delivered a Termination Notice to the
Investor, (c) the date of an Automatic Termination, and (d) the date that all of
the Warrants have been exercised.

         "Termination Fee" shall have the meaning as set forth in Section 2.6.

         "Termination Notice" shall have the meaning as set forth in Section
2.3.12.

         "Third Party Report" shall have the meaning set forth in Section 3.2.4.

         "Trading Volume " shall mean the volume of shares of the Company's
Common Stock that trade between 9:30 AM and 4:00 PM, New York City Time, on any
Business Day, and shall expressly exclude any shares trading during "after
hours" trading.

         "Transaction Documents" shall have the meaning set forth in Section 9.

         "Transfer Agent" shall have the meaning set forth in Section 6.10.

         "Transfer Agent Instructions" shall mean the Company's instructions to
its transfer agent, substantially in the form attached as EXHIBIT T, or such
other form as agreed upon by the parties.

         "Trigger Price" shall have the meaning set forth in Section 2.3.1(b).

         "Truncated Pricing Period" shall have the meaning set forth in Section
2.3.11(d).

         "Truncated Put Share Amount" shall have the meaning set forth in
Section 2.3.11(b).

         "Unlegended Share Certificates" shall mean a certificate or
certificates (or electronically delivered shares, as appropriate) (in
denominations as instructed by Investor) representing the shares of Common Stock
to which the Investor is then entitled to receive, registered in the name of
Investor or its nominee (as instructed by Investor) and not containing a
restrictive legend or stop transfer order, including but not limited to the Put
Shares for the applicable Put and Warrant Shares.

<PAGE>

         "Use of Proceeds Schedule" shall have the meaning as set forth in
Section 3.2.4, attached hereto as EXHIBIT L.

         "Volume Limitations" shall have the meaning set forth in Section
2.3.1(b).

         "Warrant Shares" shall mean the Common Stock issued or issuable upon
exercise of the Warrants.

         "Warrants" shall mean Purchase Warrants and Commitment Warrants.

         2.       PURCHASE AND SALE OF COMMON STOCK.

                  2.1      OFFER TO SUBSCRIBE.

                  Subject to the terms and conditions herein and the
satisfaction of the conditions to closing set forth in Sections 2.2 and 2.3
below, Investor hereby agrees to purchase such amounts of Common Stock and
accompanying Warrants as the Company may, in its sole and absolute discretion,
from time to time elect to issue and sell to Investor according to one or more
Puts pursuant to Section 2.3 below.

                  2.2      INVESTMENT COMMITMENT.

                           2.2.1    INVESTMENT COMMITMENT CLOSING. The closing
of this Agreement (the "Investment Commitment Closing") shall be deemed to occur
when this Agreement and the Registration Rights Agreement have been executed by
both Investor and the Company, the Transfer Agent Instructions have been
executed by both the Company and the Transfer Agent, and the other Conditions to
Investor's Obligations set forth in Section 2.2.2 below have been met.

                           2.2.2    CONDITIONS TO INVESTOR'S OBLIGATIONS. As a
prerequisite to the Investment Commitment Closing and the Investor's obligations
hereunder, all of the following (the "Conditions to Investor's Obligations")
shall have been satisfied prior to or concurrently with the Company's execution
and delivery of this Agreement:

                  (a)      the following documents shall have been delivered to
                           the Investor: (i) the Registration Rights Agreement
                           (executed by the Company and Investor), (ii) the
                           Investment Commitment Opinion of Counsel (signed by
                           the Company's counsel), (iii) the Transfer Agent
                           Instructions (executed by the Company and the
                           Transfer Agent), and (iv) a Secretary's Certificate
                           as to (A) the resolutions of the Company's board of
                           directors authorizing this transaction, (B) the
                           Company's Certificate of Incorporation, and (C) the
                           Company's Bylaws;

                  (b)      this Investment Agreement, accepted by the Company,
                           shall have been received by the Investor;

                  (c)      [Intentionally Left Blank].

                  (d)      other than continuing losses described in the Risk
                           Factors set forth in the Disclosure Documents
                           (provided for in Section 3.2.4), as of the Closing
                           there have been no material adverse changes in the
                           Company's business prospects or financial condition
                           since the date of the last balance sheet included in
                           the Disclosure Documents, including but not limited
                           to incurring material liabilities; and

                  (e)      the representations and warranties of the Company in
                           this Agreement shall be true and correct in all
                           material respects and the conditions to Investor's
                           obligations set forth in this Section 2.2.2 shall
                           have been satisfied as of such Closing; and the
                           Company shall deliver an Officer's Certificate,
                           signed by an officer of the Company, to such effect
                           to the Investor.

<PAGE>

                  2.3      PUTS OF COMMON SHARES TO THE INVESTOR.

                           2.3.1    PROCEDURE TO EXERCISE A PUT. Subject to the
Individual Put Limit, the Maximum Offering Amount and the Cap Amount (if
applicable), and the other conditions and limitations set forth in this
Agreement, at any time beginning on the date on which the Registration Statement
is declared effective by the SEC (the "Effective Date"), the Company may, in its
sole and absolute discretion, elect to exercise one or more Puts according to
the following procedure, provided that each subsequent Put Date after the first
Put Date shall be no sooner than five (5) Business Days following the preceding
Pricing Period End Date:

                                    (a)      DELIVERY OF ADVANCE PUT NOTICE. At
least ten (10) Business Days but not more than twenty (20) Business Days prior
to any intended Put Date (unless otherwise agreed in writing by the Investor),
the Company shall deliver advance written notice (the "Advance Put Notice," the
form of which is attached hereto as EXHIBIT E, the date of such Advance Put
Notice being the "Advance Put Notice Date") to Investor stating the Put Date for
which the Company shall, subject to the limitations and restrictions contained
herein, exercise a Put and stating the number of shares of Common Stock (subject
to the Individual Put Limit and the Maximum Put Dollar Amount) which the Company
intends to sell to the Investor for the Put (the "Intended Put Share Amount").

         The Company may, at its option, also designate in any Advance Put
Notice (i) a maximum dollar amount of Common Stock, not to exceed $2,000,000,
which it shall sell to Investor during the Put (the "Company Designated Maximum
Put Dollar Amount") and/or (ii) a minimum purchase price per Put Share at which
the Investor may purchase shares of Common Stock pursuant to such Put Notice (a
"Company Designated Minimum Put Share Price"). The Company Designated Minimum
Put Share Price, if applicable, shall be no greater than the lesser of (i) 80%
of the Closing Bid Price of the Company's common stock on the Business Day
immediately preceding the Advance Put Notice Date, or (ii) the Closing Bid Price
of the Company's common stock on the Business Day immediately preceding the
Advance Put Notice Date minus $0.125. The Company may decrease (but not
increase) the Company Designated Minimum Put Share Price for a Put at any time
by giving the Investor written notice of such decrease not later than 12:00
Noon, New York City time, on the Business Day immediately preceding the Business
Day that such decrease is to take effect. A decrease in the Company Designated
Minimum Put Share Price shall have no retroactive effect on the determination of
Trigger Prices and Excluded Days for days preceding the Business Day that such
decrease takes effect.

         Notwithstanding the above, if, at the time of delivery of an Advance
Put Notice, more than two (2) Calendar Months have passed since the date of the
previous Put Closing, such Advance Put Notice shall provide at least twenty (20)
Business Days notice of the intended Put Date, unless waived in writing by the
Investor. In order to effect delivery of the Advance Put Notice, the Company
shall (i) send the Advance Put Notice by facsimile on such date so that such
notice is received by the Investor by 6:00 p.m., New York, NY time, and (ii)
surrender such notice on such date to a courier for overnight delivery to the
Investor (or two (2) day delivery in the case of an Investor residing outside of
the U.S.). Upon receipt by the Investor of a facsimile copy of the Advance Put
Notice, the Investor shall, within two (2) Business Days, send, via facsimile, a
confirmation of receipt (the "Advance Put Notice Confirmation," the form of
which is attached hereto as EXHIBIT F) of the Advance Put Notice to the Company
specifying that the Advance Put Notice has been received and affirming the
intended Put Date and the Intended Put Share Amount.

                                    (b)      PUT SHARE AMOUNT. The "Put Share
Amount" is the number of shares of Common Stock that the Investor shall be
obligated to purchase in a given Put, and shall equal the lesser of (i) the
Intended Put Share Amount, and (ii) the Individual Put Limit. The "Individual
Put Limit" shall equal the lesser of (i) 1,500,000 shares, (ii) 15% of the sum
of the aggregate daily reported Trading Volumes in the outstanding Common Stock
on the Company's Principal Market, excluding any block trades of 20,000 or more
shares of Common Stock, for all Evaluation Days (as defined below) in the
Pricing Period, (iii) the number of Put Shares which, when multiplied by their
respective Put Share Prices, equals the Maximum Put Dollar Amount, and (iv) the
9.9% Limitation, but in no event shall the Individual Put Limit exceed 15% of
the sum of the aggregate daily reported Trading Volumes in the outstanding
Common Stock on the Company's Principal Market, excluding any block trades of
20,000 or more shares of Common Stock, for the twenty (20) Business Days
immediately preceding the Put Date (this limitation, together with the
limitation in (i) immediately above, are collectively referred to herein

<PAGE>

as the "Volume Limitations"). Company agrees not to trade Common Stock or
arrange for Common Stock to be traded for the purpose of artificially
increasing the Volume Limitations.

         For purposes of this Agreement:

                  "Trigger Price" for any Pricing Period shall mean the greater
of (i) the Company Designated Minimum Put Share Price, plus $0.075, or (ii) the
Company Designated Minimum Put Share Price divided by .91.

                  An "Excluded Day" shall mean each Business Day during a
Pricing Period where the lowest intra-day trading price of the Common Stock is
less than the Trigger Price.

                  An "Evaluation Day" shall mean each Business Day during a
Pricing Period that is not an Excluded Day.

                                    (c)      PUT SHARE PRICE. The purchase price
for the Put Shares (the "Put Share Price") shall equal the lesser of (i) the
Market Price for such Put, minus $0.075, or (ii) 91% of the Market Price for
such Put, but shall in no event be less than the Company Designated Minimum Put
Share Price for such Put, if applicable.

                                    (d)      DELIVERY OF PUT NOTICE. After
delivery of an Advance Put Notice, on the Put Date specified in the Advance Put
Notice the Company shall deliver written notice (the "Put Notice," the form of
which is attached hereto as EXHIBIT G) to Investor stating (i) the Put Date,
(ii) the Intended Put Share Amount as specified in the Advance Put Notice (such
exercise a "Put"), (iii) the Company Designated Maximum Put Dollar Amount (if
applicable), and (iv) the Company Designated Minimum Put Share Price (if
applicable). In order to effect delivery of the Put Notice, the Company shall
(i) send the Put Notice by facsimile on the Put Date so that such notice is
received by the Investor by 6:00 p.m., New York, NY time, and (ii) surrender
such notice on the Put Date to a courier for overnight delivery to the Investor
(or two (2) day delivery in the case of an Investor residing outside of the
U.S.). Upon receipt by the Investor of a facsimile copy of the Put Notice, the
Investor shall, within two (2) Business Days, send, via facsimile, a
confirmation of receipt (the "Put Notice Confirmation," the form of which is
attached hereto as EXHIBIT H) of the Put Notice to Company specifying that the
Put Notice has been received and affirming the Put Date and the Intended Put
Share Amount.

                                    (e)      DELIVERY OF REQUIRED PUT DOCUMENTS.
On or before the Put Date for such Put, the Company shall deliver the Required
Put Documents (as defined in Section 2.3.5 below) to the Investor (or to an
agent of Investor, if Investor so directs). Unless otherwise specified by the
Investor, the Put Shares of Common Stock shall be transmitted electronically
pursuant to such electronic delivery system as the Investor shall request;
otherwise delivery shall be by physical certificates. If the Company has not
delivered all of the Required Put Documents to the Investor on or before the Put
Date, the Put shall be automatically cancelled, unless the Investor agrees to
delay the Put Date by up to three (3) Business Days, in which case the Pricing
Period begins on the Business Day following such new Put Date. If the Company
has not delivered all of the Required Put Documents to the Investor on or before
the Put Date (or new Put Date, if applicable), and the Investor has not agreed
in writing to delay the Put Date, the Put is automatically canceled (an
"Impermissible Put Cancellation") and, unless the Put was otherwise canceled in
accordance with the terms of Section 2.3.11, the Company shall pay the Investor
$5,000 for its reasonable due diligence expenses incurred in preparation for the
canceled Put and the Company may deliver an Advance Put Notice for the
subsequent Put no sooner than ten (10) Business Days after the date that such
Put was canceled, unless otherwise agreed by the Investor.

                                    (f)      LIMITATION ON INVESTOR'S OBLIGATION
TO PURCHASE SHARES. Notwithstanding anything to the contrary in this Agreement,
in no event shall the Investor be required to purchase, and an Intended Put
Share Amount may not include, an amount of Put Shares, which when added to the
number of Put Shares acquired by the Investor pursuant to this Agreement during
the 31 days preceding the Put Date with respect to which this determination of
the permitted Intended Put Share Amount is being made, would exceed 9.99% of the
number of shares of Common Stock outstanding (on a fully diluted basis, to the
extent that inclusion of unissued shares is mandated by Section 13(d) of the
Exchange Act) on the Put Date for such Pricing Period, as determined in
accordance with Section 13(d) of the Exchange Act (the "Section 13(d)
Outstanding Share Amount"). Each Put

<PAGE>

Notice shall include a representation of the Company as to the Section 13(d)
Outstanding Share Amount on the related Put Date. In the event that the
Section 13(d) Outstanding Share Amount is different on any date during a
Pricing Period than on the Put Date associated with such Pricing Period, then
the number of shares of Common Stock outstanding on such date during such
Pricing Period shall govern for purposes of determining whether the Investor,
when aggregating all purchases of Shares made pursuant to this Agreement in
the 31 calendar days preceding such date, would have acquired more than 9.99%
of the Section 13(d) Outstanding Share Amount. The limitation set forth in
this Section 2.3.1(f) is referred to as the "9.9% Limitation."

                           2.3.2    TERMINATION OF RIGHT TO PUT. The Company's
right to require the Investor to purchase any subsequent Put Shares shall
terminate permanently (each, an "Automatic Termination") upon the occurrence of
any of the following:

                                    (a)      the Company shall not exercise a
Put or any Put thereafter if, at any time, either the Company or any director or
executive officer of the Company has engaged in a transaction or conduct related
to the Company that has resulted in (i) a Securities and Exchange Commission
enforcement action, or (ii) a civil judgment or criminal conviction for fraud or
misrepresentation, or for any other offense that, if prosecuted criminally,
would constitute a felony under applicable law;

                                    (b)      the Company shall not exercise a
Put or any Put thereafter, on any date after a cumulative time period or series
of time periods, including both Ineffective Periods and Delisting Events, that
lasts for an aggregate of four (4) months;

                                    (c)      the Company shall not exercise a
Put or any Put thereafter if at any time the Company has filed for and/or is
subject to any bankruptcy, insolvency, reorganization or liquidation proceedings
or other proceedings for relief under any bankruptcy law or any law for the
relief of debtors instituted by or against the Company or any subsidiary of the
Company;

                                    (D)      THE COMPANY SHALL NOT EXERCISE A
PUT AFTER THE SOONER OF (I) THE DATE THAT IS THREE (3) YEARS AFTER THE EFFECTIVE
DATE, OR (II) THE PUT CLOSING DATE ON WHICH THE AGGREGATE OF THE PUT DOLLAR
AMOUNTS FOR ALL PUTS EQUAL THE MAXIMUM OFFERING AMOUNT; AND

                                    (E)      THE COMPANY SHALL NOT EXERCISE A
PUT AFTER THE COMPANY HAS BREACHED ANY COVENANT IN SECTION 2.6, SECTION 6, OR
SECTION 9 HEREOF.

                                    (f)      if no Registration Statement has
been declared effective by the date that is one (1) year after the date of this
Agreement, the Automatic Termination shall occur on the date that is one (1)
year after the date of this Agreement.

                           2.3.3    PUT LIMITATIONS. The Company's right to
exercise a Put shall be limited as follows:

                                    (a)      notwithstanding the amount of any
Put, the Investor shall not be obligated to purchase any additional Put Shares
once the aggregate Put Dollar Amount paid by Investor equals the Maximum
Offering Amount;

                                    (b)      the Investor shall not be obligated
to acquire and pay for the Put Shares with respect to any Put for which the
Company has announced a subdivision or combination, including a reverse split,
of its Common Stock or has subdivided or combined its Common Stock during the
Extended Put Period;

                                    (c)      the Investor shall not be obligated
to acquire and pay for the Put Shares with respect to any Put for which the
Company has paid a dividend of its Common Stock or has made any other
distribution of its Common Stock during the Extended Put Period;

(D)      THE INVESTOR SHALL NOT BE OBLIGATED TO ACQUIRE AND PAY FOR THE PUT
SHARES WITH RESPECT TO ANY PUT FOR WHICH THE COMPANY HAS MADE, DURING THE
EXTENDED

<PAGE>

PUT PERIOD, A DISTRIBUTION OF ALL OR ANY PORTION OF ITS ASSETS OR EVIDENCES
OF INDEBTEDNESS TO THE HOLDERS OF ITS COMMON STOCK;

(E)      THE INVESTOR SHALL NOT BE OBLIGATED TO ACQUIRE AND PAY FOR THE PUT
SHARES WITH RESPECT TO ANY PUT FOR WHICH A MAJOR TRANSACTION HAS OCCURRED
DURING THE EXTENDED PUT PERIOD.

                           2.3.4    CONDITIONS PRECEDENT TO THE RIGHT OF THE
COMPANY TO DELIVER AN ADVANCE PUT NOTICE OR A PUT NOTICE AND THE OBLIGATION OF
THE INVESTOR TO PURCHASE PUT SHARES. The right of the Company to deliver an
Advance Put Notice or a Put Notice and the obligation of the Investor hereunder
to acquire and pay for the Put Shares incident to a Closing is subject to the
satisfaction, on (i) the date of delivery of such Advance Put Notice or Put
Notice and (ii) the applicable Put Closing Date, of each of the following
conditions:

                  (a)      the Company's Common Stock shall be listed for and
                           actively trading on the O.T.C. Bulletin Board, the
                           Nasdaq Small Cap Market, the Nasdaq National Market
                           or the New York Stock Exchange and the Put Shares
                           shall be so listed, and to the Company's knowledge
                           there is no notice of any suspension or delisting
                           with respect to the trading of the shares of Common
                           Stock on such market or exchange;

                  (b)      the Company shall have satisfied any and all
                           obligations pursuant to the Registration Rights
                           Agreement, including, but not limited to, the filing
                           of the Registration Statement with the SEC with
                           respect to the resale of all Registrable Securities
                           and the requirement that the Registration Statement
                           shall have been declared effective by the SEC for the
                           resale of all Registrable Securities and the Company
                           shall have satisfied and shall be in compliance with
                           any and all obligations pursuant to this Agreement
                           and the Warrants;

                  (c)      the representations and warranties of the Company are
                           true and correct in all material respects as if made
                           on such date and the conditions to Investor's
                           obligations set forth in this Section 2.3.4 are
                           satisfied as of such Closing, and the Company shall
                           deliver a certificate, signed by an officer of the
                           Company, to such effect to the Investor;

                  (d)      the Company shall have reserved for issuance a
                           sufficient number of Common Shares for the purpose of
                           enabling the Company to satisfy any obligation to
                           issue Common Shares pursuant to any Put and to effect
                           exercise of the Warrants;

                  (e)      the Registration Statement is not subject to an
                           Ineffective Period as defined in the Registration
                           Rights Agreement, the prospectus included therein is
                           current and deliverable, and to the Company's
                           knowledge there is no notice of any investigation or
                           inquiry concerning any stop order with respect to the
                           Registration Statement; and

                  (f)      if the Aggregate Issued Shares after the Closing of
                           the Put would exceed the Cap Amount, the Company
                           shall have obtained the Stockholder 20% Approval as
                           specified in Section 6.11, if the Company's Common
                           Stock is listed on the NASDAQ Small Cap Market or
                           NMS, and such approval is required by the rules of
                           the NASDAQ.

                           2.3.5    DOCUMENTS REQUIRED TO BE DELIVERED ON THE
PUT DATE AS CONDITIONS TO CLOSING OF ANY PUT. The Closing of any Put and
Investor's obligations hereunder shall additionally be conditioned upon the
delivery to the Investor of each of the following (the "Required Put Documents")
on or before the applicable Put Date:

                                    (a)      a number of Unlegended Share
Certificates (or freely tradeable electronically delivered shares, as
appropriate) equal to the Intended Put Share Amount, in denominations of not
more than 50,000 shares per certificate;

                                    (b)      the following documents: Put
Opinion of Counsel, Officer's Certificate, Put Notice, Registration Opinion, and
any report or disclosure required under Section 2.3.6 or Section 2.5;
<PAGE>

                                    (c)      all documents, instruments and
other writings required to be delivered on or before the Put Date pursuant to
any provision of this Agreement in order to implement and effect the
transactions contemplated herein.

                           2.3.6    ACCOUNTANT'S LETTER AND REGISTRATION
                                    OPINION.

                                    (a)      The Company shall have caused to be
delivered to the Investor, (i) whenever required by Section 2.3.6(b) or by
Section 2.5.3, and (ii) on the date that is three (3) Business Days prior to
each Put Date (the "Registration Opinion Deadline"), an opinion of the Company's
independent counsel, in substantially the form of EXHIBIT R (the "Registration
Opinion"), addressed to the Investor stating, inter alia, that no facts
("Material Facts") have come to such counsel's attention that have caused it to
believe that the Registration Statement is subject to an Ineffective Period or
to believe that the Registration Statement, any Supplemental Registration
Statement (as each may be amended, if applicable), and any related prospectuses,
contain an untrue statement of material fact or omits a material fact required
to make the statements contained therein, in light of the circumstances under
which they were made, not misleading. If a Registration Opinion cannot be
delivered by the Company's independent counsel to the Investor on the
Registration Opinion Deadline due to the existence of Material Facts or an
Ineffective Period, the Company shall promptly notify the Investor and as
promptly as possible amend each of the Registration Statement and any
Supplemental Registration Statements, as applicable, and any related prospectus
or cause such Ineffective Period to terminate, as the case may be, and deliver
such Registration Opinion and updated prospectus as soon as possible thereafter.
If at any time after a Put Notice shall have been delivered to Investor but
before the related Pricing Period End Date, the Company acquires knowledge of
such Material Facts or any Ineffective Period occurs, the Company shall promptly
notify the Investor and shall deliver a Put Cancellation Notice to the Investor
pursuant to Section 2.3.11 by facsimile and overnight courier by the end of that
Business Day.

                                    (b)      (i) the Company shall engage its
independent auditors to perform the procedures in accordance with the provisions
of Statement on Auditing Standards No. 71, as amended, as agreed to by the
parties hereto, and reports thereon (the "Bring Down Cold Comfort Letters") as
shall have been reasonably requested by the Investor with respect to certain
financial information contained in the Registration Statement and shall have
delivered to the Investor such a report addressed to the Investor, on the date
that is three (3) Business Days prior to each Put Date.

                                             (ii)     in the event that the
Investor shall have requested delivery of an Agreed Upon Procedures Report
pursuant to Section 2.5.3, the Company shall engage its independent auditors to
perform certain agreed upon procedures and report thereon as shall have been
reasonably requested by the Investor with respect to certain financial
information of the Company and the Company shall deliver to the Investor a copy
of such report addressed to the Investor. In the event that the report required
by this Section 2.3.6(b) cannot be delivered by the Company's independent
auditors, the Company shall, if necessary, promptly revise the Registration
Statement and the Company shall not deliver a Put Notice until such report is
delivered.

                           2.3.7    INVESTOR'S OBLIGATION AND RIGHT TO PURCHASE
SHARES. Subject to the conditions set forth in this Agreement, following the
Investor's receipt of a validly delivered Put Notice, the Investor shall be
required to purchase (each a "Purchase") from the Company a number of Put Shares
equal to the Put Share Amount, in the manner described below.

                           2.3.8    MECHANICS OF PUT CLOSING. Each of the
Company and the Investor shall deliver all documents, instruments and writings
required to be delivered by either of them pursuant to this Agreement at or
prior to each Closing. Subject to such delivery and the satisfaction of the
conditions set forth in Sections 2.3.4 and 2.3.5, the closing of the purchase by
the Investor of Shares shall occur by 5:00 PM, New York City Time, on the date
which is five (5) Business Days following the applicable Pricing Period End Date
(the "Payment Due Date") at the offices of Investor. On each or before each
Payment Due Date, the Investor shall deliver to the Company, in the manner
specified in Section 8 below, the Put Dollar Amount to be paid for such Put
Shares, determined as aforesaid. The closing (each a "Put Closing") for each Put
shall occur on the date that both (i) the Company has delivered to the Investor
all Required Put Documents, and (ii) the Investor has delivered to the Company
such Put Dollar Amount and any Late Payment Amount, if applicable (each a "Put
Closing Date").
<PAGE>

If the Investor does not deliver to the Company the Put Dollar Amount for such
Put Closing on or before the Payment Due Date, then the Investor shall pay to
the Company, in addition to the Put Dollar Amount, an amount (the "Late Payment
Amount") at a rate of X% per month, accruing daily, multiplied by such Put
Dollar Amount, where "X" equals one percent (1%) for the first month following
the date in question, and increases by an additional one percent (1%) for each
month that passes after the date in question, up to a maximum of five percent
(5%) per month; provided, however, that in no event shall the amount of interest
that shall become due and payable hereunder exceed the maximum amount
permissible under applicable law In addition to any other remedies the Company
may have, in the event that the Investor fails to make payment for any shares
Put to it by the Company under this Agreement within 30 days of the date that
the Company has notified the Investor, in writing, that such payment is past
due, and the Company has complied with this Agreement in all material respects,
the Company may terminate the unexercised portion of the Commitment Warrant.

                           2.3.9    LIMITATION ON SHORT SALES. The Investor and
its Affiliates shall not engage in short sales of the Company's Common Stock;
provided, however, that the Investor may enter into any short exempt sale or any
short sale or other hedging or similar arrangement it deems appropriate with
respect to Put Shares after it receives a Put Notice with respect to such Put
Shares so long as such sales or arrangements do not involve more than the number
of such Put Shares specified in the Put Notice.

                           2.3.10   CAP AMOUNT. If the Company becomes listed on
the Nasdaq Small Cap Market or the Nasdaq National Market, then, unless the
Company has obtained Stockholder 20% Approval as set forth in Section 6.11 or
unless otherwise permitted by Nasdaq, in no event shall the Aggregate Issued
Shares exceed the maximum number of shares of Common Stock (the "Cap Amount")
that the Company can, without stockholder approval, so issue pursuant to Nasdaq
Rule 4460(i)(1)(d)(ii) (or any other applicable Nasdaq Rules or any successor
rule) (the "Nasdaq 20% Rule").

                           2.3.11   PUT CANCELLATION.

                                    (a)      MECHANICS OF PUT CANCELLATION. If
at any time during a Pricing Period the Company discovers the existence of
Material Facts or any Ineffective Period or Delisting Event occurs, the Company
shall cancel the Put (a "Put Cancellation"), by delivering written notice to the
Investor (the "Put Cancellation Notice"), attached as EXHIBIT Q, by facsimile
and overnight courier. The "Put Cancellation Date" shall be the date that the
Put Cancellation Notice is first received by the Investor, if such notice is
received by the Investor by 6:00 p.m., New York, NY time, and shall be the
following date, if such notice is received by the Investor after 6:00 p.m., New
York, NY time.

                                    (b)      EFFECT OF PUT CANCELLATION. Anytime
a Put Cancellation Notice is delivered to Investor after the Put Date, the Put,
shall remain effective with respect to a number of Put Shares (the "Truncated
Put Share Amount") equal to the Individual Put Limit for the Truncated Pricing
Period.

                                    (c)      PUT CANCELLATION NOTICE
CONFIRMATION. Upon receipt by the Investor of a facsimile copy of the Put
Cancellation Notice, the Investor shall promptly send, via facsimile, a
confirmation of receipt (the "Put Cancellation Notice Confirmation," a form of
which is attached as EXHIBIT S) of the Put Cancellation Notice to the Company
specifying that the Put Cancellation Notice has been received and affirming the
Put Cancellation Date.

                                    (d)      TRUNCATED PRICING PERIOD. If a Put
Cancellation Notice has been delivered to the Investor after the Put Date, the
Pricing Period for such Put shall end at on the close of trading on the last
full trading day on the Principal Market that ends prior to the moment of
initial delivery of the Put Cancellation Notice (a "Truncated Pricing Period")
to the Investor.

                           2.3.12   INVESTMENT AGREEMENT CANCELLATION. The
Company may terminate (a "Company Termination") its right to initiate future
Puts by providing written notice ("Termination Notice") to the Investor, by
facsimile and overnight courier, at any time other than during an Extended Put
Period, provided that such termination shall have no effect on the parties'
other rights and obligations under this Agreement, the Registration Rights
Agreement or the Warrants. Notwithstanding the above, any cancellation occurring
during an Extended Put Period is governed by Section 2.3.11.

<PAGE>

                           2.3.13   RETURN OF EXCESS COMMON SHARES. In the event
that the number of Shares purchased by the Investor pursuant to its obligations
hereunder is less than the Intended Put Share Amount, the Investor shall
promptly return to the Company any shares of Common Stock in the Investor's
possession that are not being purchased by the Investor.

                  2.4      WARRANTS.

                           2.4.1    COMMITMENT WARRANTS. In partial
consideration hereof, following the execution of the Letter of Agreement dated
on or about June 19, 2000 between the Company and the Investor, the Company
issued and delivered to Investor or its designated assignees, warrants (the
"Commitment Warrants") in the form attached hereto as EXHIBIT U, or such other
form as agreed upon by the parties, to purchase 3,450,000 shares of Common
Stock. Each Commitment Warrant shall be immediately exercisable in accordance
with its terms, and shall have a term beginning on the date of issuance and
ending on date that is five (5) years thereafter. The Warrant Shares shall be
registered for resale pursuant to the Registration Rights Agreement. The
Investment Commitment Opinion of Counsel shall cover the issuance of the
Commitment Warrant and the issuance of the common stock upon exercise of the
Commitment Warrant.

         NOTWITHSTANDING ANY TERMINATION OR AUTOMATIC TERMINATION OF THIS
AGREEMENT, REGARDLESS OF WHETHER OR NOT THE REGISTRATION STATEMENT IS OR IS NOT
FILED, AND REGARDLESS OF WHETHER OR NOT THE REGISTRATION STATEMENT IS APPROVED
OR DENIED BY THE SEC, THE INVESTOR SHALL RETAIN FULL OWNERSHIP OF THE COMMITMENT
WARRANT AS PARTIAL CONSIDERATION FOR ITS COMMITMENT HEREUNDER.

                           2.4.2    PURCHASE WARRANTS. Within five (5) Business
Days of the end of each Pricing Period, the Company shall issue and deliver to
the Investor a warrant ("Purchase Warrant"), in the form attached hereto as
EXHIBIT D, or such other form as agreed upon by the parties, to purchase a
number of shares of Common Stock equal to 10% of the Put Share Amount for that
Put. Each Purchase Warrant shall be exerciseable at a price (the "Purchase
Warrant Exercise Price") which shall initially equal 110% of the Market Price
for the applicable Put, and shall have semi-annual reset provisions. Each
Purchase Warrant shall be immediately exercisable at the Purchase Warrant
Exercise Price, and shall have a term beginning on the date of issuance and
ending on the date that is five (5) years thereafter. The Warrant Shares shall
be registered for resale pursuant to the Registration Rights Agreement.

                  2.5      DUE DILIGENCE REVIEW. The Company shall make
available for inspection and review by the Investor (the "Due Diligence
Review"), advisors to and representatives of the Investor (who may or may not be
affiliated with the Investor and who are reasonably acceptable to the Company),
any underwriter participating in any disposition of Common Stock on behalf of
the Investor pursuant to the Registration Statement, any Supplemental
Registration Statement, or amendments or supplements thereto or any blue sky,
NASD or other filing, all financial and other records, all filings with the SEC,
and all other corporate documents and properties of the Company as may be
reasonably necessary for the purpose of such review, and cause the Company's
officers, directors and employees to supply all such information reasonably
requested by the Investor or any such representative, advisor or underwriter in
connection with such Registration Statement (including, without limitation, in
response to all questions and other inquiries reasonably made or submitted by
any of them), prior to and from time to time after the filing and effectiveness
of the Registration Statement for the sole purpose of enabling the Investor and
such representatives, advisors and underwriters and their respective accountants
and attorneys to conduct initial and ongoing due diligence with respect to the
Company and the accuracy of the Registration Statement.

                           2.5.1    TREATMENT OF NONPUBLIC INFORMATION. The
Company shall not disclose nonpublic information to the Investor or to its
advisors or representatives unless prior to disclosure of such information the
Company identifies such information as being nonpublic information and provides
the Investor and such advisors and representatives with the opportunity to
accept or refuse to accept such nonpublic information for review. The Company
may, as a condition to disclosing any nonpublic information hereunder, require
the Investor and its advisors and representatives to enter into a
confidentiality agreement (including an agreement with such

<PAGE>

advisors and representatives prohibiting them from trading in Common Stock
during such period of time as they are in possession of nonpublic
information) in form reasonably satisfactory to the Company and the Investor.

        Nothing herein shall require the Company to disclose nonpublic
information to the Investor or its advisors or representatives, and the Company
represents that it does not disseminate nonpublic information to any investors
who purchase stock in the Company in a public offering, to money managers or to
securities analysts, provided, however, that notwithstanding anything herein to
the contrary, the Company will, as hereinabove provided, immediately notify the
advisors and representatives of the Investor and, if any, underwriters, of any
event or the existence of any circumstance (without any obligation to disclose
the specific event or circumstance) of which it becomes aware, constituting
nonpublic information (whether or not requested of the Company specifically or
generally during the course of due diligence by and such persons or entities),
which, if not disclosed in the Prospectus included in the Registration
Statement, would cause such Prospectus to include a material misstatement or to
omit a material fact required to be stated therein in order to make the
statements therein, in light of the circumstances in which they were made, not
misleading. Nothing contained in this Section 2.5 shall be construed to mean
that such persons or entities other than the Investor (without the written
consent of the Investor prior to disclosure of such information) may not obtain
nonpublic information in the course of conducting due diligence in accordance
with the terms of this Agreement; provided, however, that in no event shall the
Investor's advisors or representatives disclose to the Investor the nature of
the specific event or circumstances constituting any nonpublic information
discovered by such advisors or representatives in the course of their due
diligence without the written consent of the Investor prior to disclosure of
such information.

                           2.5.2    DISCLOSURE OF MISSTATEMENTS AND OMISSIONS.
The Investor's advisors or representatives shall make complete disclosure to the
Investor's counsel of all events or circumstances constituting nonpublic
information discovered by such advisors or representatives in the course of
their due diligence upon which such advisors or representatives form the opinion
that the Registration Statement contains an untrue statement of a material fact
or omits a material fact required to be stated in the Registration Statement or
necessary to make the statements contained therein, in the light of the
circumstances in which they were made, not misleading. Upon receipt of such
disclosure, the Investor's counsel shall consult with the Company's independent
counsel in order to address the concern raised as to the existence of a material
misstatement or omission and to discuss appropriate disclosure with respect
thereto; provided, however, that such consultation shall not constitute the
advice of the Company's independent counsel to the Investor as to the accuracy
of the Registration Statement and related Prospectus.

                           2.5.3    PROCEDURE IF MATERIAL FACTS ARE REASONABLY
BELIEVED TO BE UNTRUE OR ARE OMITTED. In the event after such consultation the
Investor or the Investor's counsel reasonably believes that the Registration
Statement contains an untrue statement or a material fact or omits a material
fact required to be stated in the Registration Statement or necessary to make
the statements contained therein, in light of the circumstances in which they
were made, not misleading,

                                    (a)      the Company shall file with the SEC
an amendment to the Registration Statement responsive to such alleged untrue
statement or omission and provide the Investor, as promptly as practicable, with
copies of the Registration Statement and related Prospectus, as so amended, or

                                    (b)      if the Company disputes the
existence of any such material misstatement or omission, (i) the Company's
independent counsel shall provide the Investor's counsel with a Registration
Opinion and (ii) in the event the dispute relates to the adequacy of financial
disclosure and the Investor shall reasonably request, the Company's independent
auditors shall provide to the Company a letter ("Agreed Upon Procedures Report")
outlining the performance of such "agreed upon procedures" as shall be
reasonably requested by the Investor and the Company shall provide the Investor
with a copy of such letter.

                  2.6      COMMITMENT PAYMENTS.

         On the last Business Day of each six (6) Calendar Month period
following the Effective Date (each such period a "Commitment Evaluation
Period"), if the Company has not Put at least $1,000,000 in aggregate Put Dollar
Amount during that Commitment Evaluation Period, the Company, in consideration
of Investor's commitment costs, including, but not limited to, due diligence
expenses, shall pay to the Investor an amount (the "Semi-Annual Non-
<PAGE>

Usage Fee") equal to the difference of (i) $100,000, minus (ii) 10% of the
aggregate Put Dollar Amount of the Put Shares put to Investor during that
Commitment Evaluation Period. In the event that the Company delivers a
Termination Notice to the Investor or an Automatic Termination occurs, the
Company shall pay to the Investor (the "Termination Fee") the greater of (i)
the Semi-Annual Non-Usage Fee for the applicable Commitment Evaluation
Period, or (ii) the difference of (x) $200,000, minus (y) 10% of the
aggregate Put Dollar Amount of the Put Shares put to Investor during all Puts
to date, and the Company shall not be required to pay the Semi-Annual
Non-Usage Fee thereafter.

         Each Semi Annual Non-Usage Fee or Termination Fee is payable, in cash,
within five (5) business days of the date it accrued. The Company shall not be
required to deliver any payments to Investor under this subsection until
Investor has paid all Put Dollar Amounts that are then due.

         3.       REPRESENTATIONS, WARRANTIES AND COVENANTS OF INVESTOR.
Investor hereby represents and warrants to and agrees with the Company as
follows:

                  3.1      ACCREDITED INVESTOR. Investor is an accredited
investor ("Accredited Investor"), as defined in Rule 501 of Regulation D, and
has checked the applicable box set forth in Section 10 of this Agreement.

                  3.2      INVESTMENT EXPERIENCE; ACCESS TO INFORMATION;
INDEPENDENT INVESTIGATION.

                           3.2.1    ACCESS TO INFORMATION. Investor or
Investor's professional advisor has been granted the opportunity to ask
questions of and receive answers from representatives of the Company, its
officers, directors, employees and agents concerning the terms and conditions of
this Offering, the Company and its business and prospects, and to obtain any
additional information which Investor or Investor's professional advisor deems
necessary to verify the accuracy and completeness of the information received.

                           3.2.2    RELIANCE ON OWN ADVISORS. Investor has
relied completely on the advice of, or has consulted with, Investor's own
personal tax, investment, legal or other advisors and has not relied on the
Company or any of its affiliates, officers, directors, attorneys, accountants or
any affiliates of any thereof and each other person, if any, who controls any of
the foregoing, within the meaning of Section 15 of the Act for any tax or legal
advice (other than reliance on information in the Disclosure Documents as
defined in Section 3.2.4 below and on the Opinion of Counsel). The foregoing,
however, does not limit or modify Investor's right to rely upon covenants,
representations and warranties of the Company in this Agreement.

                           3.2.3    CAPABILITY TO EVALUATE. Investor has such
knowledge and experience in financial and business matters so as to enable such
Investor to utilize the information made available to it in connection with the
Offering in order to evaluate the merits and risks of the prospective
investment, which are substantial, including without limitation those set forth
in the Disclosure Documents (as defined in Section 3.2.4 below).

                           3.2.4    DISCLOSURE DOCUMENTS. Investor, in making
Investor's investment decision to subscribe for the Investment Agreement
hereunder, represents that (a) Investor has received and had an opportunity to
review (i) the Company's Annual Report on Form 10-KSB for the year ended
December 31, 1999, (ii) the Company's quarterly report on Form 10-QSB for the
quarters ended March 31, 2000, (iii) the Risk Factors, attached as EXHIBIT J,
(the "Risk Factors") (iv) the Capitalization Schedule, attached as EXHIBIT K,
(the "Capitalization Schedule") and (v) the Use of Proceeds Schedule, attached
as EXHIBIT L, (the "Use of Proceeds Schedule"); (b) Investor has read, reviewed,
and relied solely on the documents described in (a) above, the Company's
representations and warranties and other information in this Agreement,
including the exhibits, documents prepared by the Company which have been
specifically provided to Investor in connection with this Offering (the
documents described in this Section 3.2.4 (a) and (b) are collectively referred
to as the "Disclosure Documents"), and an independent investigation made by
Investor and Investor's representatives, if any; (c) Investor has, prior to the
date of this Agreement, been given an opportunity to review material contracts
and documents of the Company which have been filed as exhibits to the Company's
filings under the Act and the Exchange Act and has had an opportunity to ask
questions of and receive answers from the Company's officers and directors; and
(d) is not relying on any oral representation of the Company or any other
person, nor any written representation or assurance from the Company other than
those contained in the Disclosure Documents or incorporated herein or therein.
The foregoing, however, does not limit or modify Investor's right to rely upon
covenants, representations and warranties of the Company in
<PAGE>

Sections 5 and 6 of this Agreement. Investor acknowledges and agrees that the
Company has no responsibility for, does not ratify, and is under no
responsibility whatsoever to comment upon or correct any reports, analyses or
other comments made about the Company by any third parties, including, but
not limited to, analysts' research reports or comments (collectively, "Third
Party Reports"), and Investor has not relied upon any Third Party Reports in
making the decision to invest.

                           3.2.5    INVESTMENT EXPERIENCE; FEND FOR SELF.
Investor has substantial experience in investing in securities and it has made
investments in securities other than those of the Company. Investor acknowledges
that Investor is able to fend for Investor's self in the transaction
contemplated by this Agreement, that Investor has the ability to bear the
economic risk of Investor's investment pursuant to this Agreement and that
Investor is an "Accredited Investor" by virtue of the fact that Investor meets
the investor qualification standards set forth in Section 3.1 above. Investor
has not been organized for the purpose of investing in securities of the
Company, although such investment is consistent with Investor's purposes.

                  3.3      EXEMPT OFFERING UNDER REGULATION D.

                           3.3.1    NO GENERAL SOLICITATION. The Investment
Agreement was not offered to Investor through, and Investor is not aware of, any
form of general solicitation or general advertising, including, without
limitation, (i) any advertisement, article, notice or other communication
published in any newspaper, magazine or similar media or broadcast over
television or radio, and (ii) any seminar or meeting whose attendees have been
invited by any general solicitation or general advertising.

                           3.3.2    RESTRICTED SECURITIES. Investor understands
that the Investment Agreement is, the Common Stock and Warrants issued at each
Put Closing will be, and the Warrant Shares will be, characterized as
"restricted securities" under the federal securities laws inasmuch as they are
being acquired from the Company in a transaction exempt from the registration
requirements of the federal securities laws and that under such laws and
applicable regulations such securities may not be transferred or resold without
registration under the Act or pursuant to an exemption therefrom. In this
connection, Investor represents that Investor is familiar with Rule 144 under
the Act, as presently in effect, and understands the resale limitations imposed
thereby and by the Act.

                           3.3.3    DISPOSITION. Without in any way limiting the
representations set forth above, Investor agrees that until the Securities are
sold pursuant to an effective Registration Statement or an exemption from
registration, they will remain in the name of Investor and will not be
transferred to or assigned to any broker, dealer or depositary. Investor further
agrees not to sell, transfer, assign, or pledge the Securities (except for any
bona fide pledge arrangement to the extent that such pledge does not require
registration under the Act or unless an exemption from such registration is
available and provided further that if such pledge is realized upon, any
transfer to the pledgee shall comply with the requirements set forth herein), or
to otherwise dispose of all or any portion of the Securities unless and until:

                                    (a)      There is then in effect a
registration statement under the Act and any applicable state securities laws
covering such proposed disposition and such disposition is made in accordance
with such registration statement and in compliance with applicable prospectus
delivery requirements; or

                                    (b)      (i) Investor shall have notified
the Company of the proposed disposition and shall have furnished the Company
with a statement of the circumstances surrounding the proposed disposition to
the extent relevant for determination of the availability of an exemption from
registration, and (ii) if reasonably requested by the Company, Investor shall
have furnished the Company with an opinion of counsel, reasonably satisfactory
to the Company, that such disposition will not require registration of the
Securities under the Act or state securities laws. It is agreed that the Company
will not require the Investor to provide opinions of counsel for transactions
made pursuant to Rule 144 provided that Investor and Investor's broker, if
necessary, provide the Company with the necessary representations for counsel to
the Company to issue an opinion with respect to such transaction.

                  The Investor is entering into this Agreement for its own
account and the Investor has no present arrangement (whether or not legally
binding) at any time to sell the Common Stock to or through any person or
entity; provided, however, that by making the representations herein, the
Investor does not agree to hold the
<PAGE>

Common Stock for any minimum or other specific term and reserves the right to
dispose of the Common Stock at any time in accordance with federal and state
securities laws applicable to such disposition.

                  3.4      DUE AUTHORIZATION.

                           3.4.1    AUTHORITY. The person executing this
Investment Agreement, if executing this Agreement in a representative or
fiduciary capacity, has full power and authority to execute and deliver this
Agreement and each other document included herein for which a signature is
required in such capacity and on behalf of the subscribing individual,
partnership, trust, estate, corporation or other entity for whom or which
Investor is executing this Agreement. Investor has reached the age of majority
(if an individual) according to the laws of the state in which he or she
resides.

                           3.4.2    DUE AUTHORIZATION. Investor is duly and
validly organized, validly existing and in good standing as a limited liability
company under the laws of Georgia with full power and authority to purchase the
Securities to be purchased by Investor and to execute and deliver this
Agreement.

                           3.4.3    PARTNERSHIPS. If Investor is a partnership,
the representations, warranties, agreements and understandings set forth above
are true with respect to all partners of Investor (and if any such partner is
itself a partnership, all persons holding an interest in such partnership,
directly or indirectly, including through one or more partnerships), and the
person executing this Agreement has made due inquiry to determine the
truthfulness of the representations and warranties made hereby.

                           3.4.4    REPRESENTATIVES. If Investor is purchasing
in a representative or fiduciary capacity, the representations and warranties
shall be deemed to have been made on behalf of the person or persons for whom
Investor is so purchasing.

         4.       ACKNOWLEDGMENTS. Investor is aware that:

                  4.1      RISKS OF INVESTMENT. Investor recognizes that an
investment in the Company involves substantial risks, including the potential
loss of Investor's entire investment herein. Investor recognizes that the
Disclosure Documents, this Agreement and the exhibits hereto do not purport to
contain all the information, which would be contained in a registration
statement under the Act;

                  4.2      NO GOVERNMENT APPROVAL. No federal or state agency
has passed upon the Securities, recommended or endorsed the Offering, or made
any finding or determination as to the fairness of this transaction;

                  4.3      NO REGISTRATION, RESTRICTIONS ON TRANSFER. As of the
date of this Agreement, the Securities and any component thereof have not been
registered under the Act or any applicable state securities laws by reason of
exemptions from the registration requirements of the Act and such laws, and may
not be sold, pledged (except for any limited pledge in connection with a margin
account of Investor to the extent that such pledge does not require registration
under the Act or unless an exemption from such registration is available and
provided further that if such pledge is realized upon, any transfer to the
pledgee shall comply with the requirements set forth herein), assigned or
otherwise disposed of in the absence of an effective registration of the
Securities and any component thereof under the Act or unless an exemption from
such registration is available;

                  4.4      RESTRICTIONS ON TRANSFER. Investor may not attempt to
sell, transfer, assign, pledge or otherwise dispose of all or any portion of the
Securities or any component thereof in the absence of either an effective
registration statement or an exemption from the registration requirements of the
Act and applicable state securities laws;

                  4.5      NO ASSURANCES OF REGISTRATION. There can be no
assurance that any registration statement will become effective at the scheduled
time, or ever, or remain effective when required, and Investor acknowledges that
it may be required to bear the economic risk of Investor's investment for an
indefinite period of time;

                  4.6      EXEMPT TRANSACTION. Investor understands that the
Securities are being offered and sold in reliance on specific exemptions from
the registration requirements of federal and state law and that the
<PAGE>

representations, warranties, agreements, acknowledgments and understandings set
forth herein are being relied upon by the Company in determining the
applicability of such exemptions and the suitability of Investor to acquire such
Securities.

                  4.7      LEGENDS. The certificates representing the Put Shares
shall not bear a legend restricting the sale of transfer thereof ("Restrictive
Legend"). The certificates representing the Warrant Shares shall not bear a
Restrictive Legend unless they are issued at a time when the Registration
Statement is not effective for resale. It is understood that the certificates
evidencing any Warrant Shares issued at a time when the Registration Statement
is not effective for resale, subject to legend removal under the terms of
Section 6.8 below, shall bear the following legend (the "Legend"):

         "The securities represented hereby have not been registered under the
         Securities Act of 1933, as amended, or applicable state securities
         laws, nor the securities laws of any other jurisdiction. They may not
         be sold or transferred in the absence of an effective registration
         statement under those securities laws or pursuant to an exemption
         therefrom."

         5.       REPRESENTATIONS AND WARRANTIES OF THE COMPANY. The Company
hereby makes the following representations and warranties to Investor (which
shall be true at the signing of this Agreement, and as of any such later date as
contemplated hereunder) and agrees with Investor that, except as set forth in
the "Schedule of Exceptions" attached hereto as EXHIBIT C:

                  5.1      ORGANIZATION, GOOD STANDING, AND QUALIFICATION. The
Company is a corporation duly organized, validly existing and in good standing
under the laws of the State of Delaware, USA and has all requisite corporate
power and authority to carry on its business as now conducted and as proposed to
be conducted. The Company is duly qualified to transact business and is in good
standing in each jurisdiction in which the failure to so qualify would have a
material adverse effect on the business or properties of the Company and its
subsidiaries taken as a whole. Except as otherwise set forth in the Schedule of
Exceptions, the Company is not the subject of any pending, threatened or, to its
knowledge, contemplated investigation or administrative or legal proceeding (a
"Proceeding") by the Internal Revenue Service, the taxing authorities of any
state or local jurisdiction, or the Securities and Exchange Commission, The
National Association of Securities Dealer, Inc., The Nasdaq Stock Market, Inc.
or any state securities commission, or any other governmental entity, which have
not been disclosed in the Disclosure Documents. None of the disclosed
Proceedings, if any, will have a material adverse effect upon the Company or the
market for the Common Stock. The Company has the following subsidiaries:

                  5.2      CORPORATE CONDITION. The Company's condition is, in
all material respects, as described in the Disclosure Documents (as further set
forth in any subsequently filed Disclosure Documents, if applicable), except for
changes in the ordinary course of business and normal year-end adjustments that
are not, in the aggregate, materially adverse to the Company. Except for
continuing losses, there have been no material adverse changes to the Company's
business, financial condition, or prospects since the dates of such Disclosure
Documents. The financial statements as contained in the 10-KSB and 10-QSB have
been prepared in accordance with generally accepted accounting principles,
consistently applied (except as otherwise permitted by Regulation S-X of the
Exchange Act), subject, in the case of unaudited interim financial statements,
to customary year end adjustments and the absence of certain footnotes, and
fairly present the financial condition of the Company as of the dates of the
balance sheets included therein and the consolidated results of its operations
and cash flows for the periods then ended,. Without limiting the foregoing,
there are no material liabilities, contingent or actual, that are not disclosed
in the Disclosure Documents (other than liabilities incurred by the Company in
the ordinary course of its business, consistent with its past practice, after
the period covered by the Disclosure Documents). The Company has paid all
material taxes that are due, except for taxes that it reasonably disputes. There
is no material claim, litigation, or administrative proceeding pending or, to
the best of the Company's knowledge, threatened against the Company, except as
disclosed in the Disclosure Documents. This Agreement and the Disclosure
Documents do not contain any untrue statement of a material fact and do not omit
to state any material fact required to be stated therein or herein necessary to
make the statements contained therein or herein not misleading in the light of
the circumstances under which they were made. No event or circumstance exists
relating to the Company which, under applicable law, requires public disclosure
but which has not been so publicly announced or disclosed.
<PAGE>

                  5.3      AUTHORIZATION. All corporate action on the part of
the Company by its officers, directors and stockholders necessary for the
authorization, execution and delivery of this Agreement, the performance of all
obligations of the Company hereunder and the authorization, issuance and
delivery of the Common Stock being sold hereunder and the issuance (and/or the
reservation for issuance) of the Warrants and the Warrant Shares have been
taken, and this Agreement and the Registration Rights Agreement constitute valid
and legally binding obligations of the Company, enforceable in accordance with
their terms, except insofar as the enforceability may be limited by applicable
bankruptcy, insolvency, reorganization, or other similar laws affecting
creditors' rights generally or by principles governing the availability of
equitable remedies. The Company has obtained all consents and approvals required
for it to execute, deliver and perform each agreement referenced in the previous
sentence.

                  5.4      VALID ISSUANCE OF COMMON STOCK. The Common Stock and
the Warrants, when issued, sold and delivered in accordance with the terms
hereof, for the consideration expressed herein, will be validly issued, fully
paid and nonassessable and, based in part upon the representations of Investor
in this Agreement, will be issued in compliance with all applicable U.S. federal
and state securities laws. The Warrant Shares, when issued in accordance with
the terms of the Warrants, shall be duly and validly issued and outstanding,
fully paid and nonassessable, and based in part on the representations and
warranties of Investor, will be issued in compliance with all applicable U.S.
federal and state securities laws. The Put Shares, the Warrants and the Warrant
Shares will be issued free of any preemptive rights.

                  5.5      COMPLIANCE WITH OTHER INSTRUMENTS. The Company is not
in violation or default of any provisions of its Certificate of Incorporation or
Bylaws, each as amended and in effect on and as of the date of the Agreement, or
of any material provision of any material instrument or material contract to
which it is a party or by which it is bound or of any provision of any federal
or state judgment, writ, decree, order, statute, rule or governmental regulation
applicable to the Company, which would have a material adverse effect on the
Company's business or prospects, or on the performance of its obligations under
this Agreement or the Registration Rights Agreement. The execution, delivery and
performance of this Agreement and the other agreements entered into in
conjunction with the Offering and the consummation of the transactions
contemplated hereby and thereby will not (a) result in any such violation or be
in conflict with or constitute, with or without the passage of time and giving
of notice, either a default under any such provision, instrument or contract or
an event which results in the creation of any lien, charge or encumbrance upon
any assets of the Company, which would have a material adverse effect on the
Company's business or prospects, or on the performance of its obligations under
this Agreement, the Registration Rights Agreement, or (b) violate the Company's
Certificate of Incorporation or By-Laws or (c) violate any statute, rule or
governmental regulation applicable to the Company which violation would have a
material adverse effect on the Company's business or prospects.

                  5.6      REPORTING COMPANY. The Company is subject to the
reporting requirements of the Exchange Act, but does not have a class of
securities registered under Section 12 of the Exchange Act, and has filed all
reports required by the Exchange Act since the date the Company first became
subject to such reporting obligations. The Company undertakes to furnish
Investor with copies of such reports as may be reasonably requested by Investor
prior to consummation of this Offering and thereafter, to make such reports
available, for the full term of this Agreement, including any extensions
thereof, and for as long as Investor holds the Securities. The Company shall use
its reasonable best efforts to cause its Common Stock to become duly listed or
approved for quotation on the O.T.C. Bulletin Board as soon as practicable after
the date hereof, and in any event prior to initiating any Put. The Company has
filed all reports required under the Exchange Act. The Company has not furnished
to the Investor any material nonpublic information concerning the Company.

                  5.7      CAPITALIZATION. The capitalization of the Company as
of the date hereof, is, and the capitalization as of the Closing, subject to
exercise of any outstanding warrants and/or exercise of any outstanding stock
options, after taking into account the offering of the Securities contemplated
by this Agreement and all other share issuances occurring prior to this
Offering, will be, as set forth in the Capitalization Schedule as set forth in
EXHIBIT K. There are no securities or instruments containing anti-dilution or
similar provisions that will be triggered by the issuance of the Securities.
Except as disclosed in the Capitalization Schedule, as of the date of this
Agreement, (i) there are no outstanding options, warrants, scrip, rights to
subscribe for, calls or commitments of any character whatsoever relating to, or
securities or rights convertible into or exercisable or exchangeable for, any
shares of capital stock of the Company or any of its subsidiaries, or
arrangements by which the Company or any of its subsidiaries is or may become
bound to issue additional shares of capital stock of the Company or any of its
<PAGE>

subsidiaries, and (ii) there are no agreements or arrangements under which the
Company or any of its subsidiaries is obligated to register the sale of any of
its or their securities under the Act (except the Registration Rights
Agreement).

                  5.8      INTELLECTUAL PROPERTY. The Company has valid,
unrestricted and exclusive ownership of or rights to use the patents,
trademarks, trademark registrations, trade names, copyrights, know-how,
technology and other intellectual property necessary to the conduct of its
business. EXHIBIT M lists all patents, trademarks, trademark registrations,
trade names and copyrights of the Company. The Company has granted such licenses
or has assigned or otherwise transferred a portion of (or all of) such valid,
unrestricted and exclusive patents, trademarks, trademark registrations, trade
names, copyrights, know-how, technology and other intellectual property
necessary to the conduct of its business as set forth in EXHIBIT M. The Company
has been granted licenses, know-how, technology and/or other intellectual
property necessary to the conduct of its business as set forth in EXHIBIT M. To
the best of the Company's knowledge after due inquiry, the Company is not
infringing on the intellectual property rights of any third party, nor is any
third party infringing on the Company's intellectual property rights. There are
no restrictions in any agreements, licenses, franchises, or other instruments
that preclude the Company from engaging in its business as presently conducted.

                  5.9      USE OF PROCEEDS. As of the date hereof, the Company
expects to use the proceeds from this Offering (less fees and expenses) for the
purposes and in the approximate amounts set forth on the Use of Proceeds
Schedule set forth as EXHIBIT L hereto. These purposes and amounts are estimates
and are subject to change without notice to any Investor.

                  5.10     NO RIGHTS OF PARTICIPATION. No person or entity,
including, but not limited to, current or former stockholders of the Company,
underwriters, brokers, agents or other third parties, has any right of first
refusal, preemptive right, right of participation, or any similar right to
participate in the financing contemplated by this Agreement which has not been
waived.

                  5.11     COMPANY ACKNOWLEDGMENT. The Company hereby
acknowledges that Investor may elect to hold the Securities for various periods
of time, as permitted by the terms of this Agreement, the Warrants, and other
agreements contemplated hereby, and the Company further acknowledges that
Investor has made no representations or warranties, either written or oral, as
to how long the Securities will be held by Investor or regarding Investor's
trading history or investment strategies.

                  5.12     NO ADVANCE REGULATORY APPROVAL. The Company
acknowledges that this Investment Agreement, the transaction contemplated hereby
and the Registration Statement contemplated hereby have not been approved by the
SEC, or any other regulatory body and there is no guarantee that this Investment
Agreement, the transaction contemplated hereby and the Registration Statement
contemplated hereby will ever be approved by the SEC or any other regulatory
body. The Company is relying on its own analysis and is not relying on any
representation by Investor that either this Investment Agreement, the
transaction contemplated hereby or the Registration Statement contemplated
hereby has been or will be approved by the SEC or other appropriate regulatory
body.

                  5.13     UNDERWRITER'S FEES AND RIGHTS OF FIRST REFUSAL. The
Company is not obligated to pay any compensation or other fees, costs or related
expenditures in cash or securities to any underwriter, broker, agent or other
representative other than the Investor in connection with this Offering.

                  5.14     AVAILABILITY OF SUITABLE FORM FOR REGISTRATION. The
Company is currently eligible and agrees to maintain its eligibility to register
the resale of its Common Stock on a registration statement on a suitable form
under the Act.

                  5.15     NO INTEGRATED OFFERING. Neither the Company, nor any
of its affiliates, nor any person acting on its or their behalf, has directly or
indirectly made any offers or sales of any of the Company's securities or
solicited any offers to buy any security under circumstances that would prevent
the parties hereto from consummating the transactions contemplated hereby
pursuant to an exemption from registration under Regulation D of the Act or
would require the issuance of any other securities to be integrated with this
Offering under the Rules of
<PAGE>

the SEC. The Company has not engaged in any form of general solicitation or
advertising in connection with the offering of the Common Stock or the
Warrants.

                  5.16     FOREIGN CORRUPT PRACTICES. Neither the Company, nor
any of its subsidiaries, nor any director, officer, agent, employee or other
person acting on behalf of the Company or any subsidiary has, in the course of
its actions for, or on behalf of, the Company, used any corporate funds for any
unlawful contribution, gift, entertainment or other unlawful expenses relating
to political activity; made any direct or indirect unlawful payment to any
foreign or domestic government official or employee from corporate funds;
violated or is in violation of any provision of the U.S. Foreign Corrupt
Practices Act of 1977, as amended; or made any bribe, rebate, payoff, influence
payment, kickback or other unlawful payment to any foreign or domestic
government official or employee.

                  5.17     KEY EMPLOYEES. Each "Key Employee" (as defined in
EXHIBIT N) is currently serving the Company in the capacity disclosed in EXHIBIT
N. No Key Employee, to the best knowledge of the Company and its subsidiaries,
is, or is now expected to be, in violation of any material term of any
employment contract, confidentiality, disclosure or proprietary information
agreement, non-competition agreement, or any other contract or agreement or any
restrictive covenant, and the continued employment of each Key Employee does not
subject the Company or any of its subsidiaries to any liability with respect to
any of the foregoing matters. No Key Employee has, to the best knowledge of the
Company and its subsidiaries, any intention to terminate his employment with, or
services to, the Company or any of its subsidiaries.

                  5.18     REPRESENTATIONS CORRECT. The foregoing
representations, warranties and agreements are true, correct and complete in all
material respects, and shall survive any Put Closing and the issuance of the
shares of Common Stock thereby.

                  5.19     TAX STATUS. The Company has made or filed all federal
and state income and all other tax returns, reports and declarations required by
any jurisdiction to which it is subject (unless and only to the extent that the
Company has set aside on its books provisions reasonably adequate for the
payment of all unpaid and unreported taxes) and has paid all taxes and other
governmental assessments and charges that are material in amount, shown or
determined to be due on such returns, reports and declarations, except those
being contested in good faith and as set aside on its books provision reasonably
adequate for the payment of all taxes for periods subsequent to the periods to
which such returns, reports or declarations apply. There are no unpaid taxes in
any material amount claimed to be due by the taxing authority of any
jurisdiction, and the officers of the Company know of no basis for any such
claim.

                  5.20     TRANSACTIONS WITH AFFILIATES. Except as set forth in
the Disclosure Documents, none of the officers, directors, or employees of the
Company is presently a party to any transaction with the Company (other than for
services as employees, officers and directors), including any contract,
agreement or other arrangement providing for the furnishing of services to or
by, providing for rental of real or personal property to or from, or otherwise
requiring payments to or from any officer, director or such employee or, to the
knowledge of the Company, any corporation, partnership, trust or other entity in
which any officer, director, or any such employee has a substantial interest or
is an officer, director, trustee or partner.

                  5.21     APPLICATION OF TAKEOVER PROTECTIONS. The Company and
its board of directors have taken all necessary action, if any, in order to
render inapplicable any control share acquisition, business combination or other
similar anti-takeover provision under Delaware law which is or could become
applicable to the Investor as a result of the transactions contemplated by this
Agreement, including, without limitation, the issuance of the Common Stock, any
exercise of the Warrants and ownership of the Common Shares and Warrant Shares.
The Company has not adopted and will not adopt any "poison pill" provision that
will be applicable to Investor as a result of transactions contemplated by this
Agreement.

                  5.22     OTHER AGREEMENTS. The Company has not, directly or
indirectly, made any agreements with the Investor under a subscription in the
form of this Agreement for the purchase of Common Stock, relating to the terms
or conditions of the transactions contemplated hereby or thereby except as
expressly set forth herein, respectively, or in exhibits hereto or thereto.

<PAGE>

                  5.23     MAJOR TRANSACTIONS. There are no other Major
Transactions currently pending or contemplated by the Company.

                  5.24     FINANCINGS. There are no other financings currently
pending or contemplated by the Company.

                  5.25     SHAREHOLDER AUTHORIZATION. The Company shall, at its
next annual shareholder meeting following its listing on either the Nasdaq Small
Cap Market or the Nasdaq National Market, or at a special meeting to be held as
soon as practicable thereafter, use its best efforts to obtain approval of its
shareholders to (i) authorize the issuance of the full number of shares of
Common Stock which would be issuable under this Agreement and eliminate any
prohibitions under applicable law or the rules or regulations of any stock
exchange, interdealer quotation system or other self-regulatory organization
with jurisdiction over the Company or any of its securities with respect to the
Company's ability to issue shares of Common Stock in excess of the Cap Amount
(such approvals being the "20% Approval") and (ii) the increase in the number of
authorized shares of Common Stock of the Company (the "Share Authorization
Increase Approval") such that at least 50,000,000 shares can be reserved for
this Offering. In connection with such shareholder vote, the Company shall use
its best efforts to cause all officers and directors of the Company to promptly
enter into irrevocable agreements to vote all of their shares in favor of
eliminating such prohibitions. As soon as practicable after the 20% Approval and
the Share Authorization Increase Approval, the Company agrees to use its best
efforts to reserve 50,000,000 shares of Common Stock for issuance under this
Agreement.

                  5.26     ACKNOWLEDGMENT OF LIMITATIONS ON PUT AMOUNTS. The
Company understands and acknowledges that the amounts available under this
Investment Agreement are limited, among other things, based upon the liquidity
of the Company's Common Stock traded on its Principal Market.

         6.       COVENANTS OF THE COMPANY

                  6.1      INDEPENDENT AUDITORS. The Company shall, until at
least the Termination Date, maintain as its independent auditors an accounting
firm authorized to practice before the SEC.

                  6.2      CORPORATE EXISTENCE AND TAXES. The Company shall,
until at least the Termination Date, maintain its corporate existence in good
standing and, once it becomes a "Reporting Issuer" (defined as a Company which
files periodic reports under the Exchange Act), remain a Reporting Issuer
(provided, however, that the foregoing covenant shall not prevent the Company
from entering into any merger or corporate reorganization as long as the
surviving entity in such transaction, if not the Company, assumes the Company's
obligations with respect to the Common Stock and has Common Stock listed for
trading on a stock exchange or on Nasdaq and is a Reporting Issuer) and shall
pay all its taxes when due except for taxes which the Company disputes.

                  6.3      REGISTRATION RIGHTS. The Company will enter into a
registration rights agreement covering the resale of the Common Shares and the
Warrant Shares substantially in the form of the Registration Rights Agreement
attached as EXHIBIT A.

                  6.4      ASSET TRANSFERS. The Company shall not (i) transfer,
sell, convey or otherwise dispose of any of its material assets to any
subsidiary except for a cash or cash equivalent consideration and for a proper
business purpose or (ii) transfer, sell, convey or otherwise dispose of any of
its material assets to any Affiliate, as defined below, during the Term of this
Agreement. For purposes hereof, "Affiliate" shall mean any officer of the
Company, director of the Company or owner of twenty percent (20%) or more of the
Common Stock or other securities of the Company.

                  6.5      RIGHTS OF FIRST REFUSAL.

                           6.5.1    CAPITAL RAISING LIMITATIONS. During the
period from the date of this Agreement until the date that is one year after the
earlier of (a) the Put Closing Date on which the sum of the aggregate Put Share
Price for all Put Shares equal the Maximum Offering Amount, (b) the date that
the Company has delivered a Termination Notice to the Investor, or (c) the date
of an Automatic Termination, the Company shall not issue or sell, or agree to
issue or sell Equity Securities (as defined below), for cash in private capital
raising transactions without

<PAGE>

obtaining the prior written approval of the Investor of the Offering (the
limitations referred to in this subsection 6.5.1 are collectively referred to
as the "Capital Raising Limitations"). For purposes hereof, the following
shall be collectively referred to herein as, the "Equity Securities": (i)
Common Stock or any other equity securities, (ii) any debt or equity
securities which are convertible into, exercisable or exchangeable for, or
carry the right to receive additional shares of Common Stock or other equity
securities, or (iii) any securities of the Company pursuant to an equity line
structure or format similar in nature to this Offering.

                           6.5.2    INVESTOR'S RIGHT OF FIRST REFUSAL. For any
private capital raising transactions of Equity Securities which close after the
date hereof and on or prior to the date that is one (1) year after the earlier
of (a) the Put Closing Date on which the sum of the aggregate Put Share Price
for all Put Shares equal the Maximum Offering Amount, (b) the date that the
Company has delivered a Termination Notice to the Investor, or (c) the date of
an Automatic Termination, not including any warrants issued in conjunction with
this Investment Agreement, the Company agrees to deliver to Investor, at least
ten (10) days prior to the closing of such transaction, written notice
describing the proposed transaction, including the terms and conditions thereof,
and providing the Investor and its affiliates an option (the "Right of First
Refusal") during the ten (10) day period following delivery of such notice to
purchase the securities being offered in such transaction on the same terms as
contemplated by such transaction.

                           6.5.3    EXCEPTIONS TO CAPITAL RAISING LIMITATIONS
AND RIGHTS OF FIRST REFUSAL. Notwithstanding the above, neither the Capital
Raising Limitations nor the Rights of First Refusal shall apply to any
transaction involving issuances of securities in connection with a merger,
consolidation, acquisition or sale of assets, or in connection with any
strategic partnership or joint venture (the primary purpose of which is not to
raise equity capital), or in connection with the disposition or acquisition of a
business, product or license by the Company or exercise of options by employees,
consultants or directors, or a primary underwritten offering of the Company's
Common Stock, or the transactions set forth on Schedule 6.5.1. The Capital
Raising Limitations and Rights of First Refusal also shall not apply to (a) the
issuance of securities upon exercise or conversion of the Company's options,
warrants or other convertible securities outstanding as of the date hereof, (b)
the grant of additional options or warrants, or the issuance of additional
securities, under any Company stock option or restricted stock plan for the
benefit of the Company's employees, directors or consultants, or (c) the
issuance of debt securities, with no equity feature, incurred solely for working
capital purposes. If the Investor, at any time, is more than five (5) business
days late in paying any Put Dollar Amounts that are then due, the Investor shall
not be entitled to the benefits of Sections 6.5.1 and 6.5.2 above until the date
that the Investor has paid all Put Dollar Amounts that are then due.

                  6.6      FINANCIAL 10-KSB STATEMENTS, ETC. AND CURRENT REPORTS
ON FORM 8-K. The Company shall deliver to the Investor copies of its annual
reports on Form 10-KSB, and quarterly reports on Form 10-QSB and shall deliver
to the Investor current reports on Form 8-K within two (2) days of filing for
the Term of this Agreement.

                  6.7      OPINION OF COUNSEL. Investor shall, concurrent with
the Investment Commitment Closing, receive an opinion letter from the Company's
legal counsel, in the form attached as EXHIBIT B, or in such form as agreed upon
by the parties, and shall, concurrent with each Put Date, receive an opinion
letter from the Company's legal counsel, in the form attached as EXHIBIT I or in
such form as agreed upon by the parties.

                  6.8      REMOVAL OF LEGEND. If the certificates representing
any Securities are issued with a restrictive Legend in accordance with the terms
of this Agreement, the Legend shall be removed and the Company shall issue a
certificate without such Legend to the holder of any Security upon which it is
stamped, and a certificate for a security shall be originally issued without the
Legend, if (a) the sale of such Security is registered under the Act, or (b)
such holder provides the Company with an opinion of counsel, in form, substance
and scope customary for opinions of counsel in comparable transactions (the
reasonable cost of which shall be borne by the Investor), to the effect that a
public sale or transfer of such Security may be made without registration under
the Act, or (c) such holder provides the Company with reasonable assurances that
such Security can be sold pursuant to Rule 144. Each Investor agrees to sell all
Securities, including those represented by a certificate(s) from which the
Legend has been removed, or which were originally issued without the Legend,
pursuant to an effective registration statement and to deliver a prospectus in
connection with such sale or in compliance with an exemption from the
registration requirements of the Act.

<PAGE>

                  6.9      LISTING. Subject to the remainder of this Section
6.9, the Company shall ensure that its shares of Common Stock (including all
Warrant Shares and Put Shares) are listed and available for trading on the
O.T.C. Bulletin Board. Thereafter, the Company shall (i) use its best efforts to
continue the listing and trading of its Common Stock on the O.T.C. Bulletin
Board or to become eligible for and listed and available for trading on the
Nasdaq Small Cap Market, the NMS, or the New York Stock Exchange ("NYSE"); and
(ii) comply in all material respects with the Company's reporting, filing and
other obligations under the By-Laws or rules of the National Association of
Securities Dealers ("NASD") and such exchanges, as applicable.

                  6.10     THE COMPANY'S INSTRUCTIONS TO TRANSFER AGENT. The
Company will instruct the Transfer Agent of the Common Stock (the "Transfer
Agent"), by delivering instructions in the form of EXHIBIT T hereto, to issue
certificates, registered in the name of each Investor or its nominee, for the
Put Shares and Warrant Shares in such amounts as specified from time to time by
the Company upon any exercise by the Company of a Put and/or exercise of the
Warrants by the holder thereof. Such certificates shall not bear a Legend unless
issuance with a Legend is permitted by the terms of this Agreement and Legend
removal is not permitted by Section 6.8 hereof and the Company shall cause the
Transfer Agent to issue such certificates without a Legend. Nothing in this
Section shall affect in any way Investor's obligations and agreement set forth
in Sections 3.3.2 or 3.3.3 hereof to resell the Securities pursuant to an
effective registration statement and to deliver a prospectus in connection with
such sale or in compliance with an exemption from the registration requirements
of applicable securities laws. If (a) an Investor provides the Company with an
opinion of counsel, which opinion of counsel shall be in form, substance and
scope customary for opinions of counsel in comparable transactions, to the
effect that the Securities to be sold or transferred may be sold or transferred
pursuant to an exemption from registration or (b) an Investor transfers
Securities, pursuant to Rule 144, to a transferee which is an accredited
investor, the Company shall permit the transfer, and, in the case of Put Shares
and Warrant Shares, promptly instruct its transfer agent to issue one or more
certificates in such name and in such denomination as specified by such
Investor. The Company acknowledges that a breach by it of its obligations
hereunder will cause irreparable harm to an Investor by vitiating the intent and
purpose of the transaction contemplated hereby. Accordingly, the Company
acknowledges that the remedy at law for a breach of its obligations under this
Section 6.10 will be inadequate and agrees, in the event of a breach or
threatened breach by the Company of the provisions of this Section 6.10, that an
Investor shall be entitled, in addition to all other available remedies, to an
injunction restraining any breach and requiring immediate issuance and transfer,
without the necessity of showing economic loss and without any bond or other
security being required.

                  6.11     STOCKHOLDER 20% APPROVAL. Prior to the closing of any
Put that would cause the Aggregate Issued Shares to exceed the Cap Amount, if
required by the rules of NASDAQ because the Company's Common Stock is listed on
NASDAQ, the Company shall obtain approval of its stockholders to authorize (i)
the issuance of the full number of shares of Common Stock which would be
issuable pursuant to this Agreement but for the Cap Amount and eliminate any
prohibitions under applicable law or the rules or regulations of any stock
exchange, interdealer quotation system or other self-regulatory organization
with jurisdiction over the Company or any of its securities with respect to the
Company's ability to issue shares of Common Stock in excess of the Cap Amount
(such approvals being the "Stockholder 20% Approval").

                  6.12     PRESS RELEASE. The Company agrees that the Investor
shall have the right to review and comment upon any press release issued by the
Company in connection with the Offering which approval shall not be unreasonably
withheld by Investor.

                  6.13     CHANGE IN LAW OR POLICY. IN THE EVENT OF A CHANGE IN
LAW, OR POLICY OF THE SEC, AS EVIDENCED BY A NO-ACTION LETTER OR OTHER WRITTEN
STATEMENTS OF THE SEC OR THE NASD WHICH CAUSES THE INVESTOR TO BE UNABLE TO
PERFORM ITS OBLIGATIONS HEREUNDER, THIS AGREEMENT SHALL BE AUTOMATICALLY
TERMINATED AND NO TERMINATION FEE SHALL BE DUE, PROVIDED THAT NOTWITHSTANDING
ANY TERMINATION UNDER THIS SECTION 6.13, THE INVESTOR SHALL RETAIN FULL
OWNERSHIP OF THE COMMITMENT WARRANT AS CONSIDERATION FOR ITS COMMITMENT
HEREUNDER.

         7.       INVESTOR COVENANT/MISCELLANEOUS.

<PAGE>

                  7.1      REPRESENTATIONS AND WARRANTIES SURVIVE THE CLOSING;
SEVERABILITY. Investor's and the Company's representations and warranties shall
survive the Investment Date and any Put Closing contemplated by this Agreement
notwithstanding any due diligence investigation made by or on behalf of the
party seeking to rely thereon. In the event that any provision of this Agreement
becomes or is declared by a court of competent jurisdiction to be illegal,
unenforceable or void, or is altered by a term required by the Securities
Exchange Commission to be included in the Registration Statement, this Agreement
shall continue in full force and effect without said provision; provided that if
the removal of such provision materially changes the economic benefit of this
Agreement to the Investor, this Agreement shall terminate.

                  7.2      SUCCESSORS AND ASSIGNS. This Agreement shall not be
assignable without the Company's written consent. If assigned, the terms and
conditions of this Agreement shall inure to the benefit of and be binding upon
the respective successors and assigns of the parties. Nothing in this Agreement,
express or implied, is intended to confer upon any party other than the parties
hereto or their respective successors and assigns any rights, remedies,
obligations, or liabilities under or by reason of this Agreement, except as
expressly provided in this Agreement. Investor may assign Investor's rights
hereunder, in connection with any private sale of the Common Stock of such
Investor, so long as, as a condition precedent to such transfer, the transferee
executes an acknowledgment agreeing to be bound by the applicable provisions of
this Agreement in a form acceptable to the Company and provides an original copy
of such acknowledgment to the Company.

                  7.3      EXECUTION IN COUNTERPARTS PERMITTED. This Agreement
may be executed in any number of counterparts, each of which shall be
enforceable against the parties actually executing such counterparts, and all of
which together shall constitute one (1) instrument.

                  7.4      TITLES AND SUBTITLES; GENDER. The titles and
subtitles used in this Agreement are used for convenience only and are not to be
considered in construing or interpreting this Agreement. The use in this
Agreement of a masculine, feminine or neither pronoun shall be deemed to include
a reference to the others.

                  7.5      WRITTEN NOTICES, ETC. Any notice, demand or request
required or permitted to be given by the Company or Investor pursuant to the
terms of this Agreement shall be in writing and shall be deemed given when
delivered personally, or by facsimile or upon receipt if by overnight or two (2)
day courier, addressed to the parties at the addresses and/or facsimile
telephone number of the parties set forth at the end of this Agreement or such
other address as a party may request by notifying the other in writing;
provided, however, that in order for any notice to be effective as to the
Investor such notice shall be delivered and sent, as specified herein, to all
the addresses and facsimile telephone numbers of the Investor set forth at the
end of this Agreement or such other address and/or facsimile telephone number as
Investor may request in writing.

                  7.6      EXPENSES. Except as set forth in the Registration
Rights Agreement, each of the Company and Investor shall pay all costs and
expenses that it respectively incurs, with respect to the negotiation,
execution, delivery and performance of this Agreement.

                  7.7      ENTIRE AGREEMENT; WRITTEN AMENDMENTS REQUIRED. This
Agreement, including the Exhibits attached hereto, the Common Stock
certificates, the Warrants, the Registration Rights Agreement, and the other
documents delivered pursuant hereto constitute the full and entire understanding
and agreement between the parties with regard to the subjects hereof and
thereof, and no party shall be liable or bound to any other party in any manner
by any warranties, representations or covenants, whether oral, written, or
otherwise except as specifically set forth herein or therein. Except as
expressly provided herein, neither this Agreement nor any term hereof may be
amended, waived, discharged or terminated other than by a written instrument
signed by the party against whom enforcement of any such amendment, waiver,
discharge or termination is sought.

                  7.8      ACTIONS AT LAW OR EQUITY; JURISDICTION AND VENUE. The
parties acknowledge that any and all actions, whether at law or at equity, and
whether or not said actions are based upon this Agreement between the parties
hereto, shall be filed in any state or federal court sitting in Atlanta,
Georgia. Georgia law shall govern both the proceeding as well as the
interpretation and construction of the Transaction Documents and the transaction
as a whole. In any litigation between the parties hereto, the prevailing party,
as found by the court, shall be entitled to an award of all attorney's fees and
costs of court. Should the court refuse to find a prevailing party, each party
shall bear its own legal fees and costs.
<PAGE>

         8.       SUBSCRIPTION AND WIRING INSTRUCTIONS; IRREVOCABILITY.

                  (a)      WIRE TRANSFER OF SUBSCRIPTION FUNDS. Investor shall
                           deliver Put Dollar Amounts (as payment towards any
                           Put Share Price) by wire transfer, to the Company
                           pursuant to a wire instruction letter to be provided
                           by the Company, and signed by the Company.

                  (b)      IRREVOCABLE SUBSCRIPTION. Investor hereby
                           acknowledges and agrees, subject to the provisions of
                           any applicable laws providing for the refund of
                           subscription amounts submitted by Investor, that this
                           Agreement is irrevocable and that Investor is not
                           entitled to cancel, terminate or revoke this
                           Agreement or any other agreements executed by such
                           Investor and delivered pursuant hereto, and that this
                           Agreement and such other agreements shall survive the
                           death or disability of such Investor and shall be
                           binding upon and inure to the benefit of the parties
                           and their heirs, executors, administrators,
                           successors, legal representatives and assigns. If the
                           Securities subscribed for are to be owned by more
                           than one person, the obligations of all such owners
                           under this Agreement shall be joint and several, and
                           the agreements, representations, warranties and
                           acknowledgments herein contained shall be deemed to
                           be made by and be binding upon each such person and
                           his heirs, executors, administrators, successors,
                           legal representatives and assigns.

         9.       INDEMNIFICATION.

         In consideration of the Investor's execution and delivery of the
Investment Agreement, the Registration Rights Agreement and the Warrants (the
"Transaction Documents") and acquiring the Securities thereunder and in addition
to all of the Company's other obligations under the Transaction Documents, the
Company shall defend, protect, indemnify and hold harmless Investor and all of
its stockholders, officers, directors, employees and direct or indirect
investors and any of the foregoing person's agents, members, partners or other
representatives (including, without limitation, those retained in connection
with the transactions contemplated by this Agreement) (collectively, the
"Indemnitees") from and against any and all actions, causes of action, suits,
claims, losses, costs, penalties, fees, liabilities and damages, and expenses in
connection therewith (irrespective of whether any such Indemnitee is a party to
the action for which indemnification hereunder is sought), and including
reasonable attorney's fees and disbursements (the "Indemnified Liabilities"),
incurred by any Indemnitee as a result of, or arising out of, or relating to (a)
any misrepresentation or breach of any representation or warranty made by the
Company in the Transaction Documents or any other certificate, instrument or
documents contemplated hereby or thereby, (b) any breach of any covenant,
agreement or obligation of the Company contained in the Transaction Documents or
any other certificate, instrument or document contemplated hereby or thereby,
(c) any cause of action, suit or claim, derivative or otherwise, by any
stockholder of the Company based on a breach or alleged breach by the Company or
any of its officers or directors of their fiduciary or other obligations to the
stockholders of the Company, or (d) claims made by third parties against any of
the Indemnitees based on a violation of Section 5 of the Securities Act caused
by the integration of the private sale of common stock to the Investor and the
public offering pursuant to the Registration Statement.

         To the extent that the foregoing undertaking by the Company may be
unenforceable for any reason, the Company shall make the maximum contribution to
the payment and satisfaction of each of the Indemnified Liabilities which it
would be required to make if such foregoing undertaking was enforceable which is
permissible under applicable law.

         Promptly after receipt by an Indemnified Party of notice of the
commencement of any action pursuant to which indemnification may be sought, such
Indemnified Party will, if a claim in respect thereof is to be made against the
other party (hereinafter "Indemnitor") under this Section 9, deliver to the
Indemnitor a written notice of the commencement thereof and the Indemnitor shall
have the right to participate in and to assume the defense thereof with counsel
reasonably selected by the Indemnitor, provided, however, that an Indemnified
Party shall have the right to retain its own counsel, with the reasonably
incurred fees and expenses of such counsel to be paid by the Indemnitor, if
representation of such Indemnified Party by the counsel retained by the
Indemnitor would be inappropriate due to actual or potential conflicts of
interest between such Indemnified Party and any other party

<PAGE>

represented by such counsel in such proceeding. The failure to deliver
written notice to the Indemnitor within a reasonable time of the commencement
of any such action, if prejudicial to the Indemnitor's ability to defend such
action, shall relieve the Indemnitor of any liability to the Indemnified
Party under this Section 9, but the omission to so deliver written notice to
the Indemnitor will not relieve it of any liability that it may have to any
Indemnified Party other than under this Section 9 to the extent it is
prejudicial.

                           [INTENTIONALLY LEFT BLANK]

<PAGE>

         10.      ACCREDITED INVESTOR. Investor is an "accredited investor"
because (check all applicable boxes):

         (a)      [ ]      it is an organization described in Section
                           501(c)(3) of the Internal Revenue Code, or a
                           corporation, limited duration company, limited
                           liability company, business trust, or partnership not
                           formed for the specific purpose of acquiring the
                           securities offered, with total assets in excess of
                           $5,000,000.

         (b)      [ ]      any trust, with total assets in excess of
                           $5,000,000, not formed for the specific purpose of
                           acquiring the securities offered, whose purchase is
                           directed by a sophisticated person who has such
                           knowledge and experience in financial and business
                           matters that he is capable of evaluating the merits
                           and risks of the prospective investment.

         (c)      [  ]     a natural person, who

                  [  ]     is a director, executive officer or general partner
                           of the issuer of the securities being offered or sold
                           or a director, executive officer or general partner
                           of a general partner of that issuer.

                  [  ]     has an individual net worth, or joint net worth
                           with that person's spouse, at the time of his
                           purchase exceeding $1,000,000.

                  [  ]      had an individual income in excess of $200,000 in
                           each of the two most recent years or joint income
                           with that person's spouse in excess of $300,000 in
                           each of those years and has a reasonable expectation
                           of reaching the same income level in the current
                           year.

         (d)      [  ]     an entity each equity owner of which is an entity
                           described in a - b above or is an individual who
                           could check one (1) of the last three (3) boxes under
                           subparagraph (c) above.

         (e)      [  ]     other [specify] ____________________________________.

<PAGE>

         The undersigned hereby subscribes the Maximum Offering Amount and
acknowledges that this Agreement and the subscription represented hereby shall
not be effective unless accepted by the Company as indicated below.

         IN WITNESS WHEREOF, the undersigned Investor does represent and certify
under penalty of perjury that the foregoing statements are true and correct and
that Investor by the following signature(s) executed this Agreement.

Dated this 15th day of August, 2000.

SWARTZ PRIVATE EQUITY, LLC

By: ____________________________________
           Eric S. Swartz, Manager

SECURITY DELIVERY INSTRUCTIONS:
Swartz Private Equity, LLC
C/o Eric S. Swartz
200 Roswell Summit, Suite 285
1080 Holcomb Bridge Road
Roswell, GA 30076
Telephone: (770) 640-8130

THIS AGREEMENT IS ACCEPTED BY THE COMPANY IN THE AMOUNT OF THE MAXIMUM OFFERING
AMOUNT ON THE 15TH DAY OF AUGUST, 2000.

                                THEHEALTHCHANNEL.COM

                                By:____________________________________________
                                     Donald Shea, CEO

                                Address: Attn: Donald Shea, CEO
                                            260 Newport Center Drive, Suite 250
                                            Newport Beach, CA 92660
                                            Telephone (949) 631-8317
                                            Facsimile (949) 719-6055

<PAGE>

                               ADVANCE PUT NOTICE

THEHEALTHCHANNEL.COM (the "Company") hereby intends, subject to the Individual
Put Limit (as defined in the Investment Agreement), to elect to exercise a Put
to sell the number of shares of Common Stock of the Company specified below, to
_____________________________, the Investor, as of the Intended Put Date written
below, all pursuant to that certain Investment Agreement (the "Investment
Agreement") by and between the Company and Swartz Private Equity, LLC dated on
or about August 15, 2000.

                    Date of Advance Put Notice: ___________________

                    Intended Put Date: ____________________________

                    Intended Put Share Amount: ____________________

                    Company Designation Maximum Put Dollar Amount (Optional):

                    _______________________________________________.

                    Company Designation Minimum Put Share Price (Optional):

                    _______________________________________________.

                              THEHEALTHCHANNEL.COM

                              By:______________________________________________
                                   Donald Shea, CEO

                              Address: Attn: Donald Shea, CEO
                                            260 Newport Center Drive, Suite 250
                                            Newport Beach, CA 92660
                                            Telephone (949) 631-8317
                                            Facsimile (949) 719-6055

<PAGE>

                       CONFIRMATION OF ADVANCE PUT NOTICE

_________________________________, the Investor, hereby confirms receipt of
THEHEALTHCHANNEL.COM's (the "Company") Advance Put Notice on the Advance Put
Date written below, and its intention to elect to exercise a Put to sell shares
of common stock ("Intended Put Share Amount") of the Company to the Investor, as
of the intended Put Date written below, all pursuant to that certain Investment
Agreement (the "Investment Agreement") by and between the Company and Swartz
Private Equity, LLC dated on or about August 15, 2000.

                 Date of Confirmation: _____________________

                 Date of Advance Put Notice: _______________

                 Intended Put Date: ________________________

                 Intended Put Share Amount: ________________

                 Company Designation Maximum Put Dollar Amount (Optional):
                 ___________________________________________.

                 Company Designation Minimum Put Share Price (Optional):
                 ___________________________________________.

                                          INVESTOR(S)

                                          ____________________________________
                                          Investor's Name

                                          By: ________________________________
                                                  (Signature)
                                  Address:____________________________________

                                          ____________________________________

                                          ____________________________________

                                  Telephone No.: _____________________________

                                  Facsimile No.:  ____________________________

<PAGE>

                                   PUT NOTICE

THEHEALTHCHANNEL.COM (the "Company") hereby elects to exercise a Put to sell
shares of common stock ("Common Stock") of the Company to
_____________________________, the Investor, as of the Put Date, at the Put
Share Price and for the number of Put Shares written below, all pursuant to that
certain Investment Agreement (the "Investment Agreement") by and between the
Company and Swartz Private Equity, LLC dated on or about August 15, 2000.

                     Put Date :_________________

                     Intended Put Share Amount (from Advance Put
                     Notice):_________________
                     Common Shares

                     Company Designation Maximum Put Dollar Amount (Optional):

                     _____________________________________________.

                     Company Designation Minimum Put Share Price (Optional):

                     _____________________________________________.

Note: Capitalized terms shall have the meanings ascribed to them in this
Investment Agreement.

                          THEHEALTHCHANNEL.COM

                          By:____________________________________________
                                Donald Shea, CEO

                 Address: Attn: Donald Shea, CEO
                                  260 Newport Center Drive, Suite 250
                                  Newport Beach, CA 92660
                                  Telephone (949) 631-8317
                                  Facsimile (949) 719-6055

<PAGE>

                           CONFIRMATION OF PUT NOTICE

_________________________________, the Investor, hereby confirms receipt of
thehealthchannel.com (the "Company") Put Notice and election to exercise a Put
to sell ___________________________ shares of common stock ("Common Stock") of
the Company to Investor, as of the Put Date, all pursuant to that certain
Investment Agreement (the "Investment Agreement") by and between the Company and
Swartz Private Equity, LLC dated on or about August 15, 2000.

                      Date of this Confirmation: ________________

                      Put Date:________________

                      Number of Put Shares of
                      Common Stock to be Issued: _____________

                      Volume Evaluation Period: _____ Business Days

                      Pricing Period: _____ Business Days

                      INVESTOR(S)

                      ____________________________________________
                      Investor's Name

                      By: ________________________________________
                                   (Signature)
              Address:____________________________________

                      ____________________________________

                      ____________________________________

              Telephone No.: ___________________________________

              Facsimile No.: ____________________________________

<PAGE>

                             PUT CANCELLATION NOTICE

THEHEALTHCHANNEL.COM (the "Company") hereby cancels the Put specified below,
pursuant to that certain Investment Agreement (the "Investment Agreement") by
and between the Company and Swartz Private Equity, LLC dated on or about August
15, 2000, as of the close of trading on the date specified below (the
"Cancellation Date," which date must be on or after the date that this notice is
delivered to the Investor), provided that such cancellation shall not apply to
the number of shares of Common Stock equal to the Truncated Put Share Amount (as
defined in the Investment Agreement).

                              Cancellation Date: _____________________

                              Put Date of Put Being Canceled: __________

                              Number of Shares Put on Put Date: _________

                              Reason for Cancellation (check one):

                                    [ ] Material Facts, Ineffective Registration
                                        Period.

                                    [ ] Delisting Event

The Company understands that, by canceling this Put, it must give twenty (20)
Business Days advance written notice to the Investor before effecting the next
Put.

                              THEHEALTHCHANNEL.COM

                              By:________________________________________
                                   Donald Shea, CEO

                         Address: Attn: Donald Shea, CEO
                                           260 Newport Center Drive, Suite 250
                                           Newport Beach, CA 92660
                                           Telephone (949) 631-8317
                                           Facsimile (949) 719-6055

<PAGE>

                      PUT CANCELLATION NOTICE CONFIRMATION

The undersigned Investor to that certain Investment Agreement (the "Investment
Agreement") by and between the thehealthchannel.com's, and Swartz Private
Equity, LLC dated on or about August 15, 2000, hereby confirms receipt of
thehealthchannel.com's (the "Company") Put Cancellation Notice, and confirms the
following:

                             Date of this Confirmation: ________________

                             Put Cancellation Date: ___________________

                             INVESTOR(S)

                             ____________________________________________
                             Investor's Name

                             By: _________________________________
                                   (Signature)

                   Address:____________________________________

                           ____________________________________

                           ____________________________________

                   Telephone No.: ___________________________________

                   Facsimile No.: ____________________________________

<PAGE>

                           THEHEALTHCHANNEL.COM, INC.

                        EXHIBIT C: SCHEDULE OF EXCEPTION

                             SCHEDULE OF EXCEPTIONS

         This SCHEDULE OF EXCEPTIONS is issued pursuant to Section 5:
Representations and Warranties of the Company, of that certain INVESTMENT
AGREEMENT (the "Agreement") entered into as of August 15, 2000 by and between
SWARTZ PRIVATE EQUITY, LLC and thehealthchannel.com, Inc. (the "Company"), with
headquarters located at 260 Newport Center Drive, Suite 250 Newport Beach,
California 92660 and the investor (the "Investor") set forth on the execution
page of said Agreement.

SECTION 5.2       CORPORATE CONDITION

         The Company has been named as a cross-defendant in a cross-complaint
filed by Michael Grandon in an action pending in the Superior Court State of
California for the County of San Francisco, Case No. 307364. This action was
initiated by Biologix International, Ltd. against Michael Grandon on October 22,
1999 alleging causes of action against Michael Grandon for: (1) temporary
restraining order and preliminary and permanent injunction; (2) breach of
fiduciary duty; (3) fraud by intentional misrepresentation; (4) conversion; (5)
possession of personal property; (6) declaratory relief; and (7) accounting. The
claims alleged by Biologix International, Ltd. relate to the actions and conduct
of Mr. Grandon while an officer and director of Biologix International, Ltd.
thehealthchannel.com is named as a cross-defendant in the cross-complaint of
Michael Grandon in a cause of action for breach of contract based upon an
alleged employment agreement between Michael Grandon and Biologix International
Ltd. Mr. Grandon claims that this alleged employment agreement is the
responsibility of thehealthchannel.com based upon thehealthchannel.com's
purchase of the internet related assets of Biologix International Ltd.
thehealthchannel.com was served with the cross-complaint on December 14, 1999.
Mr. Grandon seeks $400,000 in damages and options to purchase one million shares
of Biologix stock

         The Company has received correspondence from the SEC alleging that
certain actions taken by BioLogix, Inc. (the owner of thehealthchannel.com
website prior to its acquisition in July, 1999), Innovative Tracking Solutions,
Inc. ("IVTX") (the previous name of thehealthchannel.com) and
thehealthchannel.com, Inc. may have been in violation of applicable federal and
state securities laws. These allegations include the unavailability of an
exemption from registration for the exchange of shares by the BioLogix
shareholders. While the Company has provided correspondence to the SEC denying
these allegations and providing an explanation regarding why the Company
believes its actions were in compliance with applicable securities laws, the SEC
has indicated that it continues to disagree with the Company's position.

SECTION 5.2.1     TRANSACTIONS WITH AFFILIATES

         The Company has a Consulting Agreement with Jeffrey Berg, a director of
the Company, whereby, for a one time payment of 22,000 shares of common stock of
the Company, Mr. Berg assists the Company in locating, negotiating, and managing
its financing.

SECTION 5.5       COMPLIANCE WITH OTHER INSTRUMENTS

<PAGE>

         The Bylaws of the Company require the Company to hold an annual meeting
         within five months after each fiscal year end. The annual meeting that
         should have been held by May 31, 2000 has been tentatively scheduled
         for October 12, 2000.

SECTION 5.7       CAPITALIZATION

The Company is obligated to register, along with the registration of the shares
contemplated by the Agreement, the following shares:

<TABLE>
<S>                                                          <C>
Investors in 506 Offering
(approximately 105 investors)                                5,072,040 shares

Laguna Pacific Partners, L.P.                                2,500,000 shares
</TABLE>

And the following shares issuable upon the exercise of a common stock warrant:

<TABLE>
<S>                                                          <C>
Institute for Medical Studies                                1,200,000 shares

Investors in 506 Offering
(approximately 105 investors)                                5,093,469  shares

Les Dube and Irene Dube                                      1,579,000 shares
</TABLE>

<PAGE>

                           THEHEALTHCHANNEL.COM, INC.

                             EXHIBIT J: RISK FACTORS

<PAGE>

RISK FACTORS

      THE SECURITIES TO BE SOLD PURSUANT TO THIS INVESTMENT AGREEMENT ARE VERY
SPECULATIVE AND INVOLVE A HIGH DEGREE OF RISK. THESE SECURITIES SHOULD BE
PURCHASED ONLY BY PEOPLE WHO CAN AFFORD THE LOSS OF THEIR ENTIRE INVESTMENT.
BEFORE PURCHASING THESE SECURITIES, YOU SHOULD CAREFULLY CONSIDER THE FOLLOWING
RISK FACTORS AND THE OTHER INFORMATION CONCERNING THEHEALTHCHANNEL.COM AND ITS
BUSINESS CONTAINED IN THIS PROSPECTUS.

THEHEALTHCHANNEL.COM HAS      Thehealthchannel.com commenced implementation of
ONLY A LIMITED OPERATING      its current business plan during the fourth
HISTORY AND IS INCURRING      quarter of 1999. Prior to July 1999 the assets
LOSSES FROM ITS OPERATIONS.   currently comprising the internet site had been
                              owned and operated by BioLogix, Inc. In April
                              1999, BioLogix launched the website deploying a
                              business plan relying upon the advertising-based
                              revenue model as many other healthcare websites
                              such as Healtheon and DrKoop.com were doing.
                              During the third quarter of 1999, our management
                              began to conclude that an advertising-based
                              revenue model could not sustain profitable
                              operations as the marketing budgets necessary to
                              attract advertisers exceeded the revenues produced
                              by these advertisers. thehealthchannel.com
                              management believes this failure was because the
                              marketing budgets needed to attract advertisers
                              exceeded the revenues produced by these
                              advertisers. As a result, in July of 1999
                              thehealthchannel.com commenced deployment of the
                              new business plan described in this prospectus.
                              This new business plan has virtually no operating
                              history and its financial success will be subject
                              to all the risks inherent in the establishment of
                              a new business enterprise. Additionally,
                              thehealthchannel.com has operated at a loss for
                              all of the periods for which financial statements
                              are presented in this prospectus. The likelihood
                              of success of thehealthchannel.com must be
                              considered in the light of the problems, expenses,
                              difficulties, complications, and delays frequently
                              encountered in connection with the startup and
                              growth of a new business, and the competitive
                              environment in which thehealthchannel.com
                              operates. Unanticipated problems, expenses, and
                              delays are frequently encountered in establishing
                              a new business and marketing and developing
                              internet based products and services. These
                              include competition, the need to develop customer
                              support capabilities and market expertise,
                              setbacks in technology development, market
                              acceptance, sales, and marketing. An additional
                              risk factor associated with this new business plan
                              is that some of the proposed strategies have never
                              been implemented and thus it would be speculative
                              to predict whether such strategies will ever be
                              successful. The failure of thehealthchannel.com to
                              meet any of these conditions will have a
                              materially adverse effect upon our business and
                              may force us to reduce or curtail operations. We
                              cannot assure you that the company will ever
                              operate profitably. See "Management's Discussion
                              and Analysis of Financial Condition and Results of
                              Operations," and "Our Business--Competition."

FEDERAL INCOME TAX RISKS.     The transfer of Shares may have adverse federal
                              income tax consequences to the transferor. Each
                              prospective investor must obtain the advice of the
                              investor's own tax advisor concerning the matters
                              discussed in this Memorandum and the effect of an
                              investment in the Company on the investor's
                              personal tax situation.

THERE IS INTENSE              The online commerce industry is new, rapidly
COMPETITION IN THE            evolving and intensely competitive, which we
ON-LINE HEALTHCARE            expect to intensify in the future. Barriers to
BUSINESS.                     entry are minimal, allowing current and new
                              competitors to launch new Web sites at a
                              relatively low cost. We compete with other
                              companies which have health care websites. These
                              competitors include WebMD, DrKoop.com,
                              InteliHealth, OnHealth, and YourHealth.com. These
                              competitors have longer operating histories,
                              larger customer bases, greater brand name
                              recognition and significantly greater financial,
                              marketing and other resources than we do. In
                              addition, other companies may be acquired by,
                              receive

<PAGE>

                              investments from or enter into other commercial
                              relationships with larger, well-established and
                              well-financed companies as use of the Internet
                              and other online services increases. Our
                              competitors may be able to devote greater
                              resources to marketing and promotional
                              campaigns, and devote substantially more
                              resources to Web site and systems development
                              than we can. We cannot assure you that we will
                              be able to compete successfully against current
                              and future competitors, and competitive
                              pressures may have a material adverse effect on
                              our business, prospects, financial condition
                              and results of operations. Further as a
                              strategic response to changes in the
                              competitive environment, our management may,
                              from time to time, make certain service or
                              marketing decisions or acquisitions that could
                              have a material adverse effect on its business,
                              prospects, financial condition and results of
                              operations. New technologies and the expansion
                              of existing technologies may increase the
                              competitive pressures on thehealthchannel.com.
                              In addition, companies that control access to
                              transactions through network access or Web
                              browsers could promote our competitors or
                              charge us a substantial fee for inclusion. See
                              "Business of the Company--Competition."

ELECTRONIC COMMERCE           The secure transmission of confidential
SECURITY RISKS                information over public networks is critical to
                              electronic commerce. The Company's systems and
                              operations are vulnerable to damage or
                              interruption from fire, flood, other natural
                              disasters, power loss, telecommunications failure,
                              break-ins and similar events. If a person
                              circumvents the Company's security measures, he or
                              she could jeopardize the security of confidential
                              information stored on the Company's systems,
                              misappropriate proprietary information or cause
                              interruptions in the Company's operations, which
                              could damage the Company's reputation and expose
                              the Company to a risk of loss or liability.

THERE IS A RISK OF SYSTEM     The ability to provide timely information and
FAILURE FOR OUR WEBSITE       continuous updates depends on the efficient and
                              uninterrupted operation of our computer and
                              communications hardware and software systems.
                              Similarly, the ability to track, measure, and
                              report the delivery of advertisements, data and
                              other information on our website depends on the
                              efficient and uninterrupted operation of our
                              system. These systems and operations are
                              vulnerable to damage or interruption from human
                              error, natural disasters, telecommunication
                              failures, break-ins, sabotage, computer viruses,
                              intentional acts of vandalism and similar events.
                              We have a disaster recovery plan that generates a
                              two week tape rotation and full backup for all
                              tape devices. Historical data requiring long term
                              storage will be backed up by CD-Rom. Two copies
                              will be made for each archive created. Data on the
                              local area network is backed up to a tape drive on
                              a nightly basis. Additionally, we have a state of
                              the art network that is designed to run 24 hours a
                              day, seven days a week. Drives in the servers can
                              be switched without shutting down the system.
                              Backup generators are in place that will enable
                              the network to shut down properly in the event of
                              total power loss. The network can run
                              independently for up to ten minutes of a brown
                              out. Despite these precautions, there is always
                              the danger that human error or sabotage could
                              substantially disrupt our web site which could
                              cause a loss of visitors to our site, damage to
                              our systems, and bad publicity.

WE MAY ACQUIRE BUSINESSES     We may acquire companies with operations that are
THAT ARE SUBJECT TO           subject to regulation by federal agencies and
GOVERNMENTAL REGULATIONS      various state, local and private consumer
                              protection and other regulatory authorities. There
                              can be no assurance that any such regulatory
                              requirements will not have a material adverse
                              effect on our business, financial condition or
                              results of operations.

TECHNOLOGICAL CHANGE          Although the Company is aware of no pending or
                              prospective technological change that would
                              adversely affect its business, new developments in
                              technology could have

<PAGE>

                              a material adverse affect on the sale of some or
                              all of the Company's services or products or
                              render its services noncompetitive or obsolete,
                              and there can be no assurance that the Company
                              will be able to develop or acquire new or
                              improved services or systems which may be required
                              to remain competitive. The occurrence of such
                              technological change could have a material adverse
                              affect on the Company.

OUR BUSINESS IS DEPENDENTON   The Internet based information market is new and
THE CONTINUED GROWTH AND      rapidly evolving. Our business would be materially
USE OF THE INTERNET, AS WELL  adversely affected if Internet usage does not
AS THE EFFICIENT OPERATION    continue to grow or grows slower than currently
OF THE INTERNET.              projected. Internet usage may be inhibited for a
                              number of reasons, such as:

                                     -    inadequate network infrastructure;
                                     -    security concerns;
                                     -    inconsistent quality of service; and
                                     -    unavailability of cost-effective,
                                          high-speed access to the Internet.

                              Our website viewers depend on Internet service
                              providers, online service providers and other web
                              site operators for access to our website. Many of
                              these services have experienced significant
                              service outages in the past and could experience
                              service outages, delays, and other difficulties
                              due to system failures unrelated to our systems.
                              These occurrences could cause our viewers to
                              perceive the Internet in general or our web site
                              in particular as an unreliable medium and,
                              therefore, cause them to use other media or other
                              websites to obtain information. We also depend on
                              certain information providers to deliver
                              information and data feeds on a timely basis.
                              Our web site could experience disruptions or
                              interruptions in service due to the failure or
                              delay in the transmission or receipt of this
                              information, which could have a material adverse
                              effect on our business, results of operations,
                              and financial condition.

THERE ARE CURRENTLY LEGAL     Certain existing laws or regulations specifically
UNCERTAINTIES RELATING TO     regulate communications or commerce on the
THE INTERNET                  Internet. Further, laws and regulations that
                              address issues such as user privacy, pricing,
                              online content regulation, taxation and the
                              characteristics and quality of online products and
                              services are under consideration by federal,
                              state, local, and foreign governments and
                              agencies. Several telecommunications companies
                              have petitioned the Federal Communications
                              Commissioner to regulate Internet service
                              providers and online services providers in a
                              manner similar to the regulation of long distance
                              telephone carriers and to impose access fees on
                              such companies. Such regulation, if imposed, could
                              increase the cost of transmitting data over the
                              Internet. Moreover, it may take years to determine
                              the extent to which existing laws relating to
                              issues such as intellectual property ownership and
                              infringement, libel, and personal privacy are
                              applicable to the Internet. The Federal Trade
                              Commission and government agencies in certain
                              states have been investigating certain Internet
                              companies regarding their use of personal
                              information. We could incur additional expenses if
                              any new regulations regarding the use of personal
                              information are introduced or these agencies chose
                              to investigate our privacy practices. Any new laws
                              or regulations relating to the Internet, or
                              certain application or interpretation of existing
                              laws could decrease the growth in the use of the
                              Internet, decrease the demand for the our web site
                              or otherwise materially adversely affect our
                              business.

INTERNET SECURITY CONCERNS    Concern about the transmission of confidential
COULD HINDER INTERNET USE     information over the Internet has been a
                              significant barrier to electronic commerce and
                              communications over the Internet. Any
                              well-publicized compromise of security could deter
                              more people from

<PAGE>

                              using the Internet or from using it to conduct
                              transactions that involve the transmission of
                              confidential information, such as personal
                              health related information, signing up for a
                              paid subscription, or purchasing goods or
                              services. Because many of our advertisers will
                              seek to advertise on our web site to encourage
                              people to use the Internet to purchase goods or
                              services, our business, results of operations,
                              and financial condition could be materially
                              adversely affected if Internet users
                              significantly reduce their use of the Internet
                              because of security concerns. We may also incur
                              significant costs to protect our website
                              against the threat of security breaches or to
                              alleviate problems caused by such breaches.

THEHEALTHCHANNEL.COM          Our success depends, to a significant extent, upon
DEPENDS ON KEY PERSONNEL FOR  a number of key employees, including our
CRITICAL MANAGEMENT           President, Donald Shea, and our Vice President,
DECISIONS.                    Chief Operations Officer, Secretary, and Chief
                              Financial Officer, Thomas Lonergan. The loss of
                              services of one or more of these employees could
                              have a material adverse effect on our business. We
                              believe that our future success will also depend
                              in part upon our ability to attract, retain, and
                              motivate qualified personnel. Competition for such
                              personnel is intense. There can be no assurance
                              that we can attract and retain such personnel. We
                              do not have "key person" life insurance on any of
                              our employees. See "Management."

THEHEALTHCHANNEL.COM MAY      Our business is capital intensive. Our future
REQUIRE ADDITIONAL FINANCING  capital requirements will depend on many factors,
FOR ITS BUSINESS.             including cash flow from operations, competing
                              market developments, and our ability to market our
                              website successfully. Although we currently expect
                              to meet our capital needs by selling stock to
                              Swartz Private Equity, LLC, it may be necessary to
                              raise additional funds through equity or debt
                              financings. Any equity financings could result in
                              dilution to our shareholders. Debt financing may
                              result in higher interest expense. Any financing,
                              if available, may be on unfavorable terms. If we
                              cannot raise adequate funds, we may have to reduce
                              or curtail our operations.

THEHEALTHCHANNEL.COM'S        thehealthchannel.com's common stock is quoted and
COMMON STOCK IS CURRENTLY     traded on the Over-the-Counter Pink Sheets
CLASSIFIED AS A "PENNY STOCK" ("Bulletin Board"). As a result, an investor could
WHICH COULD CAUSE INVESTORS   find it more difficult to dispose of, or to obtain
TO EXPERIENCE DELAYS AND      accurate quotations as to the market value of, the
OTHER DIFFICULTIES IN TRADING stock as compared to securities which are traded
SHARES IN THE STOCK MARKET    on the NASDAQ trading market or on an exchange. In
                              addition, trading in the common stock is covered
                              by what is known as the "Penny Stock Rules." The
                              Penny Stock Rules require brokers to provide
                              additional disclosure in connection with any
                              trades involving a stock defined as a "penny
                              stock," including the delivery, prior to any penny
                              stock transaction, of a disclosure schedule
                              explaining the penny stock market and the risks
                              associated therewith. The regulations governing
                              penny stocks could limit the ability of brokers to
                              sell the shares offered in this prospectus and
                              thus the ability of the purchasers of this
                              Offering to sell these shares in the secondary
                              market. Our stock will be covered by the Penny
                              Stock Rules until it has a market price of $5.00
                              per share or more, subject to certain exceptions
                              The trading price of our stock could be subject to
                              wide fluctuations in response to quarterly
                              variations in operating results, announcement of
                              technological innovations or new products by us or
                              our competitors, and other events or factors. In
                              addition, in recent years the stock market has
                              experienced extreme price and volume fluctuations
                              that have had a substantial effect on the market
                              prices for many internet companies, which may be
                              unrelated to the operating performance of the
                              specific companies.

WE HAVE NEVER PAID            thehealthchannel.com has never paid dividends on
DIVIDENDS ON OUR COMMON       its common stock and does not plan on paying cash
STOCK AND DON'T PLAN TO PAY   dividends in the foreseeable future.
DIVIDENDS IN THE FUTURE.

<PAGE>

INVESTORS WILL EXPERIENCE     In many cases, our officers, directors, and
IMMEDIATE AND SUBSTANTIAL     present shareholders have acquired their
DILUTION.                     securities at a cost substantially less than that
                              which investors will pay for the common stock
                              offered by this prospectus. As a result, investors
                              acquiring shares registered in this prospectus
                              will likely incur immediate, substantial dilution
                              in the net tangible book value per share of the
                              common stock. The net tangible book value of a
                              share represents the amount of
                              thehealthchannel.com's tangible assets less the
                              amount of its liabilities, divided by the number
                              of shares outstanding.

THE PRICE OF THE SHARES       The securities being offered in this prospectus
OFFERED HEREBY IS DEPENDENT   are offered at the market price prevailing at the
UPON THE PRICE IN THE PUBLIC  time of the offer. The market price of these
MARKET WHICH WILL FLUCTUATE.  securities may vary and may have a limited
                              relationship, or no relationship, to our assets,
                              book value, results of operations, or other
                              established criteria of value. The offering price
                              also may not be indicative of the prices that will
                              prevail in the subsequent trading market for our
                              securities.

MOST OF OUR SHARES OF         Adjusted for the anticipated one for three reverse
COMMON STOCK OF WILL BECOME   stock split, as of July 28, 2000,
ELIGIBLE FOR PUBLIC SALE OVER thehealthchannel.com had outstanding 14,303,948
THE NEXT YEAR WHICH COULD     shares that are classified as "restricted
HAVE A DEPRESSIVE EFFECT ON   securities" as that term is defined under Rule 144
THE STOCK.                    of the Securities Act of 1933, as amended. Most of
                              these shares have been held by shareholders for at
                              least one year and may be entitled to be sold
                              under Rule 144. In addition, we are registering
                              (i) 31,250,000 shares and 4,275,000 shares
                              underlying warrants for Swartz, (ii) 1,690,680
                              shares and 2,097,823 shares underlying warrants
                              for other Selling Shareholders, (ii) 526,333
                              shares for Les Dube and Irene Dube, and (iv)
                              833,333 shares underlying warrants for Laguna
                              Pacific Partners, L.P.. If a significant number of
                              shares are offered for sale through the public
                              securities markets simultaneously, it would have a
                              depressive effect on the trading price of common
                              stock. See "Description of Securities."

SPECIAL NOTE REGARDING        Statements made in this prospectus regarding our
FORWARD LOOKING STATEMENTS.   funding requirements and the timing of and
                              potential for our business constitute forward
                              looking statements under federal securities laws.
                              Such statements are subject to certain risks and
                              uncertainties that could cause the rate at which
                              we incur expenses and conducts our business to
                              differ materially from those projected. Our
                              ability to proceed with the marketing and
                              development of our business in accordance with the
                              dates anticipated is subject to all of the risks
                              discussed in this prospectus and our ability to
                              estimate the time period for which revenues will
                              fund our operations is subject to substantial
                              uncertainty. Undue reliance should not be placed
                              on the dates and time periods discussed in this
                              prospects. These estimates are based on the
                              current expectations of our management which may
                              change in the future due to a large number of
                              unanticipated future developments.

WE MAY HAVE CONTINGENT        We have engaged in a private placement of
LIABILITIES RESULTING FROM    securities from September 1999 up to the date of
OUR RECENT PRIVATE PLACEMENT. this prospectus. During this period of time, we
                              sold securities to investors based on our most
                              recent closing price on the OTC Bulletin Board or
                              the Pink Sheets. The prices at which these
                              securities were sold fluctuated widely, based on
                              fluctuations in our closing prices. We cannot
                              preclude the possibility that an investor or
                              investors who purchased securities in the private
                              placement will claim that the Company failed to
                              fully disclose the fact that fluctuation in the
                              market for our stock would cause adjustment in the
                              price of the private placement. We believe we
                              fully disclosed this risk. In the event any
                              shareholder were to successfully prosecute an
                              action against us on this issue, it may have
                              severe and adverse effects on the Company,
                              including but not limited to impacting our ability
                              to continue as a going concern.

WE MAY NEED ADDITIONAL        We believe that the funds to be raised in this
CAPITAL.                      offering (assuming the successful

<PAGE>

                              completion of a maximum offering), together
                              with our revenues will be sufficient to provide
                              us with capital sufficient to fund our
                              short-term needs. It is likely that we will be
                              required to raise additional capital. We cannot
                              assure you that the proceeds we receive from
                              Swartz will, in fact, be available or if
                              available will be sufficient in the near term
                              or that conditions and circumstances may not
                              result in subsequent cash requirements by us,
                              or that future funds will be sufficient to
                              sustain operations and to meet growth. In the
                              event of such developments, attaining financing
                              under such conditions may not be possible, or
                              even if additional capital may be otherwise
                              available, the terms on which such capital may
                              be available may not be commercially feasible
                              or advantageous to us.

WE HAVE BEEN ADVISED BY THE   We recently received correspondence from the
SECURITIES AND EXCHANGE       Securities Exchange Commission alleging that the
COMMISSION (THE "SEC")  THAT  exchange of BioLogix shares for shares of
CERTAIN TRANSACTIONS          thehealthchannel.com may have constituted an
INVOLVING                     unregistered public offering in violation of
THEHEALTHCHANNEL.COM MAY      applicable state and federal securities laws.
HAVE BEEN IN VIOLATION OF THE While we have provided correspondence to the SEC
SECURITIES LAWS.              denying these allegations, the SEC has indicated
                              that it continues to disagree with our position.
                              If we have engaged in an unregistered public
                              offering, this would constitute a violation of the
                              Securities Act of 1933 and applicable state laws
                              and would make us potentially liable to legal
                              action by both the SEC and state security
                              regulators and our shareholders. In the event any
                              of these parties were to successfully prosecute an
                              action based on these allegations, it would have a
                              severe and adverse effect on the Company. The
                              Company may be required to pay monetary damages
                              and penalties and may be subject to a
                              court-imposed injunction, or may be forced to
                              enter into a consent decree with the SEC. In the
                              event, any of these events were to occur it would
                              likely immediately and severely impact the
                              Company, possibly impairing our ability to
                              continue as a going concern.

<PAGE>

LITIGATION                    We have been named as a cross-defendant in a
                              cross-complaint filed by Michael Grandon in an
                              action pending in the Superior Court State of
                              California for the County of San Francisco, Case
                              No. 307364. This action was initiated by BioLogix
                              International, Ltd. against Michael Grandon on
                              October 22, 1999. The complaint of BioLogix
                              International, Ltd. alleges causes of action
                              against Michael Grandon for: (1) temporary
                              restraining order and preliminary and permanent
                              injunction; (2) breach of fiduciary duty; (3)
                              fraud by intentional misrepresentation; (4)
                              conversion; (5) possession of personal property;
                              (6) declaratory relief; and (7) accounting. The
                              claims alleged by BioLogix International, Ltd.
                              relate to the actions and conduct of Mr. Grandon
                              while an officer and director of BioLogix
                              International, Ltd. We are named as a
                              cross-defendant in the cross-complaint of Michael
                              Grandon in a cause of action for breach of
                              contract based upon an alleged employment
                              agreement between Michael Grandon and BioLogix
                              International Ltd. Mr. Grandon claims that this
                              alleged employment agreement is our responsibility
                              based upon our purchase of the internet related
                              assets of BioLogix International Ltd. We were
                              served with the cross-complaint on December 14,
                              1999. Mr. Grandon seeks $400,000 in damages and
                              options to purchase one million shares of BioLogix
                              stock. We have answered the cross-complaint
                              denying the allegations of Mr. Grandon. We will
                              aggressively defend against the claims asserted by
                              Mr. Grandon.

<PAGE>

                           THEHEALTHCHANNEL.COM, INC.

                       EXHIBIT K: CAPITALIZATION SCHEDULE
                           EXHIBIT L: USE OF PROCEEDS
                        EXHIBIT M: INTELLECTUAL PROPERTY
                            EXHIBIT N: KEY EMPLOYEES

<PAGE>

                           THEHEALTHCHANNEL.COM, INC.
                             Capitalization Schedule
                              As of August 15 2000

<TABLE>

<S>                                                                           <C>
Common Stock Outstanding on August 15, 2000                                      79,724,043

         Warrants outstanding(1)                                                 11,043,469

         Shares reserved for issuance as a result of this Agreement             103,125,000

         Shares reserved to be issued                                             1,579,000

         Shares reserved for Stock Option Plan                                    5,000,000

         Total Shares Outstanding and Reserved                                  198,687,775

         Shares of Common Stock Authorized(2)                                   110,000,000

         Shares of Preferred Stock Authorized                                          None

</TABLE>

(1) Includes 3,450,000 warrants already issued to Swartz Private Equity, LLC

(2) At the next shareholder meeting in October 2000, the Company is asking its
shareholders to approve a three for one reverse stock split in October 2000 and
increase the authorized stock to 175,000,000.

<PAGE>

                           THEHEALTHCHANNEL.COM, INC.
                                 Use of Proceeds
<TABLE>

             <S>                                                     <C>
              Repayments of Bridge Loans made by Laguna
              Pacific Partners, L.P. and Les Dube and
              Irene Dube                                                 $500,000

              Research and Development                                 $9,500,000

              Marketing                                               $10,000,000

              Other Working Capital                                    $9,825,000

              Expenses of Transaction and Registration                   $175,000

              TOTAL PROCEEDS                                          $30,000,000

</TABLE>

                           THEHEALTHCHANNEL.COM, INC.
                         Intellectual Property Schedule

TRADEMARKS

U.S. Trademark Application for thehealthchannel.com     Serial Number 75772466

U.S. Trademark Application for thehealthchannel.com     Serial Number 75772326

<PAGE>

                           THEHEALTHCHANNEL.COM, INC.
                                  Key Employees

DONALD J. SHEA, PRESIDENT, CHIEF EXECUTIVE OFFICER AND CHAIRMAN. From 1995
through 1997, Mr. Shea was Marketing Consultant to Marketing Insights, Inc., a
new product development Company in Princeton, New Jersey. Prior to that he was
President of Avonwood Capital Corporation, Philadelphia, Pennsylvania, a Venture
Capital/Management Consulting firm; and President of Brilliant Enterprises,
Inc., Philadelphia, Pennsylvania, a dental products manufacturer. Mr. Shea was
also the former President and CEO of Clairol, Inc., a Division of Bristol-Myers
Squibb, former Vice-President of Bristol-Myers Squibb. Mr. Shea brings over 35
years of consumer products marketing and general management experience to the
Company.

THOMAS F. LONERGAN, MA, CHIEF OPERATING OFFICER, VICE PRESIDENT, SECRETARY,
CHIEF FINANCIAL OFFICER, AND DIRECTOR. Mr. Lonergan was the co-founder and Vice
Chairman The IQ NOW Corporation, a deliverer of healthcare information on the
Internet from 1992 through 1999. Previously, he was a Regional Director of
Cardiology for Tenet Medical Group, former Director of Clinical Services at
Downey Community Hospital, and has been a hospital administrator for 20 years.
He was responsible for $70 million budget and manages over 200 employees. For 11
years he has been an instructor and director of medical technology at Coast
College. Mr. Lonergan is co-founder of the American College of Cardiovascular
Administrators. He has an Associate of Arts (Pre-Medicine) from Cerritos Junior
College (1971), a Bachelor of Science (Pre-Medicine) from the University of
California, Irvine (1973), and an Executive Masters Degree of Business
Administration from Pepperdine University (1990).

BALAZS IMRE BODAI, M.D., DIRECTOR. From 1985 and continuing through the present,
Dr. Bodai is the Chief of Surgery at Kaiser Permanente Medical Center,
Sacramento, California. He is also President of B and B Medical Research
Technology, Inc., Sacramento, California; an Associate Clinical Professor of
Surgery at the University of California at Davis; a Consultant to COAT, Johnson
& Johnson, Newark, New Jersey; and a Senior Consultant to Sontek Medical, Inc.,
Higham, Massachusetts. "Ernie" holds a Bachelor of Science and Master of Science
Degrees from the School of Medicine at the University of California at Los
Angeles, and a Doctor of Medicine Degree from the University of California at
Davis. He is author and co-author of over 120 scientific and clinical
publications in various of the leading medical journals, author of a surgery
text book, and is well-recognized within the field of emergency and critical
care medicine.

JEFFREY H. BERG, PH.D., DIRECTOR. Dr. Berg holds an MBA and Ph.D. in Chemistry
from New York University. From September 1995 through the present, he is a
senior research analyst for M.H. Meyerson & Co., Inc. From 1991 through the
present, he is the President of Health Care Insights. Mr. Berg was Chicago
Corporation's senior medical advisor from 1991 to 1992. Mr. Berg was security
analyst for William K.

<PAGE>

Woodruff & Co. from 1990 to 1991 and Vice-President of Research for J.C.
Bradford & Co. from 1987 to 1990. From 1981 to 1987 he was Vice-President of
the Health Care Division of PA Consulting Services, Inc. of London, England,
specializing in international technology and new product surveillance,
venture capital investment, acquisition studies, and state-of-the-art for
diverse areas of health care. During the 1970s, Mr. Berg developed products
and conducted research for General Foods, the Patient Care Division of
Johnson & Johnson Products, Inc., the Consumer Products Division of Ortho
Pharmaceutical Corporation; and staffed and supervised scientists and
engineers at the R&D laboratories for development of varied medical and
health care products within the Johnson & Johnson family of companies. Dr.
Berg holds several patents in the area of biosensor and disposable electrode
technology. He has published a number of articles on topics such as
biosensors, cancer therapy, biopharmaceuticals, drug infusion devices and
industrial biotechnology. Dr. Berg serves as a liaison with the investment
banking and scientific communities.

JOSEPH SONG, M.D., F.A.C.C., DIRECTOR. From 1994 through the present, Dr. Song
has his own practice in Interventional Cardiology. From 1991 through 1994, he
was an Interventional Cardiologist with Internal Medicine Specialists Medical
Group, Inc. He is a Lecturer and Moderator at Downey Foundation Hospitals. Dr.
Song is Clinical Assistant Professor of Medicine/Cardiology at the College of
Osteopathic Medicine of the Pacific in California and a member of the Teaching
Staff of the Family Practice Internship/Residency Program at Rio Hondo/Downey
Community Hospital, California. He is certified by the American Board of
Internal Medicine and the American Board of Cardiovascular Diseases. Dr. Song
received an A.B. in Physics from Washington University in St. Louis Missouri in
1982 and his M.D. from University of Missouri-Columbia School of Medicine in
1986.<PAGE>

                                  Exhibit 10.23

                             REGISTRATION AGREEMENT

            THEHEALTHCHANNEL.COM, INC. AND SWARTZ PRIVATE EQUITY, LLC

                              Dated August 15, 2000

<PAGE>

                          REGISTRATION RIGHTS AGREEMENT

         THIS REGISTRATION RIGHTS AGREEMENT (this "Agreement") is entered into
as of August 15, 2000, by and among thehealthchannel.com, a corporation duly
incorporated and existing under the laws of the State of Delaware (the
"Company"), and the subscriber as named on the signature page hereto
(hereinafter referred to as "Subscriber").

                                    RECITALS:

         WHEREAS, pursuant to the Company's offering ("Offering") of up to
Thirty Million Dollars ($30,000,000), excluding any funds paid upon exercise of
the Warrants, of Common Stock of the Company pursuant to that certain Investment
Agreement of even date herewith (the "Investment Agreement") between the Company
and the Subscriber, the Company has agreed to sell and the Subscriber has agreed
to purchase, from time to time as provided in the Investment Agreement, shares
of the Company's Common Stock for a maximum aggregate offering amount of Thirty
Million Dollars ($30,000,000);

         WHEREAS, pursuant to the terms of the Investment Agreement, the Company
has agreed to issue to the Subscriber the Commitment Warrants and, from time to
time, the Purchase Warrants, each as defined in the Investment Agreement, to
purchase a number of shares of Common Stock, exercisable for five (5) years from
their respective dates of issuance (collectively, the "Warrants"); and

         WHEREAS, pursuant to the terms of the Investment Agreement, the Company
has agreed to provide the Subscriber with certain registration rights with
respect to the Common Stock to be issued in the Offering and the Common Stock
issuable upon exercise of the Warrants as set forth in this Agreement.

                                     TERMS:

         NOW, THEREFORE, in consideration of the mutual promises,
representations, warranties, covenants and conditions set forth in this
Agreement and for other good and valuable consideration, the receipt and
sufficiency of which is hereby acknowledged, the parties hereto agree as
follows:

         1.       CERTAIN DEFINITIONS. As used in this Agreement (including the
Recitals above), the following terms shall have the following meanings (such
meanings to be equally applicable to both singular and plural forms of the terms
defined):

                  "Additional Registration Statement" shall have the meaning set
forth in Section 3(b).

                  "Amended Registration Statement" shall have the meaning set
forth in Section 3(b).

                  "Business Day" shall have the meaning set forth in the
Investment Agreement.

                  "Closing Bid Price" shall have the meaning set forth in the
Investment Agreement.

                  "Common Stock" shall mean the common stock, par value
$0.00035, of the Company.

                  "Due Date" shall mean the date that is one hundred twenty
(120) days after the date of this Agreement.

                  "Effective Date" shall have the meaning set forth in Section
2.4.

                  "Exchange Act" shall mean the Securities Exchange Act of 1934,
as amended, together with the rules and regulations promulgated thereunder.

<PAGE>

                  "Filing Deadline" shall mean the date that is forty-five (45)
days after the date of this Agreement.

                  "Investment Agreement" shall have the meaning set forth in the
Recitals hereto.

                  "Holder" shall mean Subscriber, and any other person or entity
owning or having the right to acquire Registrable Securities or any permitted
assignee;

                  "Piggyback Registration" and "Piggyback Registration
Statement" shall have the meaning set forth in Section 4.

                  "Put" shall have the meaning as set forth in the Investment
Agreement.

                  "Register," "Registered," and "Registration" shall mean and
refer to a registration effected by preparing and filing a registration
statement or similar document in compliance with the Securities Act and pursuant
to Rule 415 under the Securities Act or any successor rule, and the declaration
or ordering of effectiveness of such registration statement or document.

                  "Registrable Securities" shall have the meaning set forth in
Section 2.1.

                  "Registration Statement" shall have the meaning set forth in
Section 2.2.

                  "Rule 144" shall mean Rule 144, as amended, promulgated under
the Securities Act.

                  "Securities Act" shall mean the Securities Act of 1933, as
amended, together with the rules and regulations promulgated thereunder.

                  "Subscriber" shall have the meaning set forth in the preamble
to this Agreement.

                  "Supplemental Registration Statement" shall have the meaning
set forth in Section 3(b).

                  "Warrants" shall have the meaning set forth in the above
Recitals.

                  "Warrant Shares" shall mean shares of Common Stock issuable
upon exercise of any Warrant.

         2.       REQUIRED REGISTRATION.

                  2.1      REGISTRABLE SECURITIES. "Registrable Securities"
shall mean those shares of the Common Stock of the Company together with any
capital stock issued in replacement of, in exchange for or otherwise in respect
of such Common Stock, that are: (i) issuable or issued to the Subscriber
pursuant to the Investment Agreement, and (ii) issuable or issued upon exercise
of the Warrants; provided, however, that notwithstanding the above, the
following shall not be considered Registrable Securities:

                           (a)      any Common Stock which would otherwise be
deemed to be Registrable Securities, if and to the extent that those shares of
Common Stock may be resold in a public transaction without volume limitations or
other material restrictions without registration under the Securities Act,
including without limitation, pursuant to Rule 144 under the Securities Act; and

                           (b)      any shares of Common Stock which have been
sold in a private transaction in which the transferor's rights under this
Agreement are not assigned.

                  2.2      FILING OF INITIAL REGISTRATION STATEMENT. The Company
shall, by the Filing Deadline, file a registration statement ("Registration
Statement") on Form SB-2 (or other suitable form, at the Company's discretion,
but subject to the reasonable approval of Subscriber), covering the resale of a
number of shares of Common Stock as Registrable Securities equal to at least
Fifty Million (50,000,000) shares of Common Stock and shall cover, to the extent
allowed by applicable law, such indeterminate number of additional shares of
Common Stock that may be issued or become issuable as Registrable Securities by
the Company pursuant to Rule 416 of the

<PAGE>

Securities Act. In the event that the Company has not filed the Registration
Statement by the Filing Deadline, then the Company shall pay to SUBSCRIBER an
amount equal to $500, in cash, FOR EACH BUSINESS DAY AFTER THE FILING
DEADLINE until such Registration Statement is filed, payable within ten (10)
BUSINESS DAYS following the end of each calendar month in which such payments
accrue.

                  2.3      [INTENTIONALLY LEFT BLANK].

                  2.4      REGISTRATION EFFECTIVE DATE. The Company shall use
its best efforts to have the Registration Statement declared effective by the
SEC (the date of such effectiveness is referred to herein as the "Effective
Date") by the Due Date.

                  2.5      [INTENTIONALLY LEFT BLANK].

                  2.6      [INTENTIONALLY LEFT BLANK].

                  2.7      SHELF REGISTRATION. The Registration Statement shall
be prepared as a "shelf" registration statement under Rule 415, and shall be
maintained effective until all Registrable Securities are resold pursuant to the
Registration Statement.

                  2.8      SUPPLEMENTAL REGISTRATION STATEMENT. Anytime the
Registration Statement does not cover a sufficient number of shares of Common
Stock to cover all outstanding Registrable Securities, the Company shall
promptly prepare and file with the SEC such Supplemental Registration Statement
and the prospectus used in connection with such registration statement as may be
necessary to comply with the provisions of the Securities Act with respect to
the disposition of all such Registrable Securities and shall use its best
efforts to cause such Supplemental Registration Statement to be declared
effective as soon as possible.

         3.       OBLIGATIONS OF THE COMPANY. Whenever required under this
Agreement to effect the registration of any Registrable Securities, the Company
shall, as expeditiously and reasonably possible:

                  (a)      Prepare and file with the Securities and Exchange
Commission ("SEC") a Registration Statement with respect to such Registrable
Securities and use its best efforts to cause such Registration Statement to
become effective and to remain effective until all Registrable Securities are
resold pursuant to such Registration Statement, notwithstanding any Termination
or Automatic Termination (as each is defined in the Investment Agreement) of the
Investment Agreement.

                  (b)      Prepare and file with the SEC such amendments and
supplements to such Registration Statement and the prospectus used in connection
with such Registration Statement ("Amended Registration Statement") or prepare
and file any additional registration statement ("Additional Registration
Statement," together with the Amended Registration Statement, "Supplemental
Registration Statements") as may be necessary to comply with the provisions of
the Securities Act with respect to the disposition of all securities covered by
such Supplemental Registration Statements or such prior registration statement
and to cover the resale of all Registrable Securities.

                  (c)      Furnish to the Holders such numbers of copies of a
prospectus, including a preliminary prospectus, in conformity with the
requirements of the Securities Act, and such other documents as they may
reasonably request in order to facilitate the disposition of Registrable
Securities owned by them.

                  (d)      Use its best efforts to register and qualify the
securities covered by such Registration Statement under such other securities or
Blue Sky laws of the jurisdictions in which the Holders are located, of such
other jurisdictions as shall be reasonably requested by the Holders of the
Registrable Securities covered by such Registration Statement and of all other
jurisdictions where legally required, provided that the Company shall not be
required in connection therewith or as a condition thereto to qualify to do
business or to file a general consent to service of process in any such states
or jurisdictions.

                  (e)      [Intentionally Omitted].

<PAGE>

                  (f)      As promptly as practicable after becoming aware of
such event, notify each Holder of Registrable Securities of the happening of
any event of which the Company has knowledge, as a result of which the
prospectus included in the Registration Statement, as then in effect, includes
an untrue statement of a material fact or omits to state a material fact
required to be stated therein or necessary to make the statements therein, in
light of the circumstances under which they were made, not misleading, use its
best efforts promptly to prepare a supplement or amendment to the Registration
Statement to correct such untrue statement or omission, and deliver a number
of copies of such supplement or amendment to each Holder as such Holder may
reasonably request.

                  (g)      Provide Holders with notice of the date that a
Registration Statement or any Supplemental Registration Statement registering
the resale of the Registrable Securities is declared effective by the SEC, and
the date or dates when the Registration Statement is no longer effective.

                  (h)      Provide Holders and their representatives the
opportunity and a reasonable amount of time, based upon reasonable notice
delivered by the Company, to conduct a reasonable due diligence inquiry of
Company's pertinent financial and other records and make available its
officers and directors for questions regarding such information as it relates
to information contained in the Registration Statement.

                  (i)      Provide Holders and their representatives the
opportunity to review the Registration Statement and all amendments or
supplements thereto prior to their filing with the SEC by giving the Holder at
least ten (10) business days advance written notice prior to such filing.

                  (j)      Provide each Holder with prompt notice of the
issuance by the SEC or any state securities commission or agency of any stop
order suspending the effectiveness of the Registration Statement or the
initiation of any proceeding for such purpose. The Company shall use its best
efforts to prevent the issuance of any stop order and, if any is issued, to
obtain the removal thereof at the earliest possible date.

                  (k)      Use its best efforts to list the Registrable
Securities covered by the Registration Statement with all securities exchanges
or markets on which the Common Stock is then listed and prepare and file any
required filing with the NASD, American Stock Exchange, NYSE and any other
exchange or market on which the Common Stock is listed.

         4.       PIGGYBACK REGISTRATION. If anytime prior to the date that
the Registration Statement is declared effective or during any Ineffective
Period (as defined in the Investment Agreement) the Company proposes to
register (including for this purpose a registration effected by the Company
for shareholders other than the Holders) any of its Common Stock under the
Securities Act in connection with the public offering of such securities
solely for cash (other than a registration relating solely for the sale of
securities to participants in a Company stock plan or a registration on Form
S-4 promulgated under the Securities Act or any successor or similar form
registering stock issuable upon a reclassification, upon a business
combination involving an exchange of securities or upon an exchange offer for
securities of the issuer or another entity), the Company shall, at such time,
promptly give each Holder written notice of such registration (a "Piggyback
Registration Statement"). Upon the written request of each Holder given by fax
within ten (10) days after mailing of such notice by the Company, the Company
shall cause to be included in such registration statement under the Securities
Act all of the Registrable Securities that each such Holder has requested to
be registered ("Piggyback Registration") to the extent such inclusion does not
violate the registration rights of any other security holder of the company
granted prior to the date hereof; provided, however, that nothing herein shall
prevent the Company from withdrawing or abandoning such registration statement
prior to its effectiveness.

         5.       LIMITATION ON OBLIGATIONS TO REGISTER UNDER A PIGGYBACK
REGISTRATION. In the case of a Piggyback Registration pursuant to an
underwritten public offering by the Company, if the managing underwriter
determines and advises in writing that the inclusion in the related Piggyback
Registration Statement of all Registrable Securities proposed to be included
would interfere with the successful marketing of the securities proposed to be
registered by the Company, then the number of such Registrable Securities to
be included in such Piggyback Registration Statement, to the extent any such
Registrable Securities may be included in such Piggyback Registration
Statement, shall be allocated among all Holders who had requested Piggyback
Registration pursuant to the terms hereof, in the proportion that the number
of Registrable Securities which each such Holder seeks to register bears to
the total number of Registrable Securities sought to be included by all
Holders. If required by the managing underwriter of
<PAGE>

such an underwritten public offering, the Holders shall enter into an
agreement limiting the number of Registrable Securities to be included in
such Piggyback Registration Statement and the terms, if any, regarding the
future sale of such Registrable Securities.

         6.       DISPUTE AS TO REGISTRABLE SECURITIES. In the event the Company
believes that shares sought to be registered under Section 2 or Section 4 by
Holders do not constitute "Registrable Securities" by virtue of Section 2.1 of
this Agreement, and the status of those shares as Registrable Securities is
disputed, the Company shall provide, at its expense, an Opinion of Counsel,
reasonably acceptable to the Holders of the Securities at issue (and
satisfactory to the Company's transfer agent to permit the sale and transfer),
that those securities may be sold immediately, without volume limitation or
other material restrictions, without registration under the Securities Act, by
virtue of Rule 144 or similar provisions.

         7.       FURNISH INFORMATION. At the Company's request, each Holder
shall furnish to the Company such information regarding Holder, the Registrable
Securities held by it, and the intended method of disposition of such securities
to the extent required to effect the registration of its Registrable Securities
or to determine that registration is not required pursuant to Rule 144 or other
applicable provision of the Securities Act. The Company shall include all
information provided by such Holder pursuant hereto in the Registration
Statement, substantially in the form supplied, except to the extent such
information is not permitted by law.

         8.       EXPENSES. All expenses, other than commissions and fees and
expenses of counsel to the selling Holders, incurred in connection with
registrations, filings or qualifications pursuant hereto, including (without
limitation) all registration, filing and qualification fees, printers' and
accounting fees, fees and disbursements of counsel for the Company, shall be
borne by the Company.

<PAGE>         9.       INDEMNIFICATION. In the event any Registrable
Securities are included in a Registration Statement under this Agreement:

                  (a)      To the extent permitted by law, the Company will
indemnify and hold harmless each Holder, the officers, directors, partners,
legal counsel, and accountants of each Holder, any underwriter (as defined in
the Securities Act, or as deemed by the Securities Exchange Commission, or as
indicated in a registration statement) for such Holder and each person, if
any, who controls such Holder or underwriter within the meaning of Section 15
of the Securities Act or the Exchange Act, against any losses, claims,
damages, or liabilities (joint or several) to which they may become subject
under the Securities Act, the Exchange Act or other federal or state law,
insofar as such losses, claims, damages, or liabilities (or actions in respect
thereof) arise out of or are based upon any of the following statements or
omissions: (i) any untrue statement or alleged untrue statement of a material
fact contained in such registration statement, including any preliminary
prospectus or final prospectus contained therein or any amendments or
supplements thereto, or (ii) the omission or alleged omission to state therein
a material fact required to be stated therein, or necessary to make the
statements therein not misleading, and the Company will reimburse each such
Holder, officer or director, underwriter or controlling person for any legal
or other expenses reasonably incurred by them in connection with investigating
or defending any such loss, claim, damage, liability, or action; provided,
however, that the indemnity agreement contained in this subsection 9(a) shall
not apply to amounts paid in settlement of any such loss, claim, damage,
liability, or action if such settlement is effected without the consent of the
Company (which consent shall not be unreasonably withheld), nor shall the
Company be liable in any such case for any such loss, claim, damage,
liability, or action to the extent that it arises out of or is based upon a
violation which occurs in reliance upon and in conformity with written
information furnished expressly for use in connection with such registration
by any such Holder, officer, director, underwriter or controlling person;
provided however, that the above shall not relieve the Company from any other
liabilities which it might otherwise have.

                  (b)      Each Holder of any securities included in such
registration being effected shall indemnify and hold harmless the Company, its
directors and officers, each underwriter and each other person, if any, who
controls (within the meaning of the Securities Act) the Company or such other
indemnified party, against any liability, joint or several, to which any such
indemnified party may become subject under the Securities Act or any other
statute or at common law, insofar as such liability (or actions in respect
thereof) arises out of or is based upon (i) any untrue statement or alleged
untrue statement of any material fact contained, on the effective date
thereof, in any registration statement under which securities were registered
under the Securities Act at the request of such Holder, any preliminary
prospectus or final prospectus contained therein, or any amendment or
supplement thereto, or (ii) any omission or alleged omission by such Holder to
state therein a material fact required to be stated therein or necessary to
make the statements therein not misleading, to the extent, but only to the
extent, that such untrue statement or alleged untrue statement or omission or
alleged omission was made in such registration statement, preliminary or final
prospectus, amendment or supplement thereto in reliance upon and in conformity
with information furnished in writing to the Company by such Holder
specifically for use therein. Such Holder shall reimburse any indemnified
party for any legal fees incurred in investigating or defending any such
liability; PROVIDED, HOWEVER, that such Holder's obligations hereunder shall
be limited to an amount equal to the proceeds to such Holder of the securities
sold in any such registration; and PROVIDED FURTHER, that no Holder shall be
required to indemnify any party against any liability arising from any untrue
or misleading statement or omission contained in any preliminary prospectus if
such deficiency is corrected in the final prospectus or for any liability
which arises out of the failure of such party to deliver a prospectus as
required by the Securities Act.

                  (c)      Promptly after receipt by an indemnified party
under this Section 9 of notice of the commencement of any action (including
any governmental action), such indemnified party will, if a claim in respect
thereof is to be made against any indemnifying party under this Section 9,
deliver to the indemnifying party a written notice of the commencement thereof
and the indemnifying party shall have the right to participate in, and, to the
extent the indemnifying party so desires, jointly with any other indemnifying
party similarly noticed, to assume, the defense thereof with counsel mutually
satisfactory to the parties; provided, however, that an indemnified party
shall have the right to retain its own counsel, with the reasonably incurred
fees and expenses of one such counsel to be paid by the indemnifying party, if
representation of such indemnified party by the counsel retained by the
indemnifying party would be inappropriate due to actual or potential
conflicting interests between such indemnified party and any other party
represented by such counsel in such proceeding. The failure to deliver written
notice to the indemnifying party within a reasonable time of the commencement
of any such action, if materially prejudicial to its ability to defend such
action, shall relieve such indemnifying party of any liability to the
indemnified party
<PAGE>

under this Section 9, but the omission so to deliver written notice to the
indemnifying party will not relieve it of any liability that it may have to
any indemnified party otherwise than under this Section 9.

                  (d)      In the event that the indemnity provided in
paragraphs (a) and/or (b) of this Section 9 is unavailable to or insufficient to
hold harmless an indemnified party for any reason, the Company and each Holder
agree to contribute to the aggregate claims, losses, damages and liabilities
(including legal or other expenses reasonably incurred in connection with
investigating or defending same) (collectively "Losses") to which the Company
and one or more of the Holders may be subject in such proportion as is
appropriate to reflect the relative fault of the Company and the Holders in
connection with the statements or omissions which resulted in such Losses.
Relative fault shall be determined by reference to whether any alleged untrue
statement or omission relates to information provided by the Company or by the
Holders. The Company and the Holders agree that it would not be just and
equitable if contribution were determined by pro rata allocation or any other
method of allocation that does not take account of the equitable considerations
referred to above. Notwithstanding the provisions of this paragraph (d), no
person guilty of fraudulent misrepresentation (within the meaning of Section
11(f) of the Securities Act) shall be entitled to contribution from any person
who was not guilty of such fraudulent misrepresentation. For purposes of this
Section 9, each person who controls a Holder of Registrable Securities within
the meaning of either the Securities Act or the Exchange Act and each director,
officer, partner, employee and agent of a Holder shall have the same rights to
contribution as such holder, and each person who controls the Company within the
meaning of either the Securities Act or the Exchange Act and each director and
officer of the Company shall have the same rights to contribution as the
Company, subject in each case to the applicable terms and conditions of this
paragraph (d).

<PAGE>

                  (e)      The obligations of the Company and Holders under this
Section 9 shall survive the resale, if any, of the Common Stock, the completion
of any offering of Registrable Securities in a Registration Statement under this
Agreement, and otherwise.

         10.      REPORTS UNDER EXCHANGE ACT. With a view to making available to
the Holders the benefits of Rule 144 promulgated under the Securities Act and
any other rule or regulation of the SEC that may at any time permit a Holder to
sell securities of the Company to the public without registration, the Company
agrees to:

                  (a)      make and keep public information available, as those
terms are understood and defined in Rule 144; and

                  (b)      use its best efforts to file with the SEC in a timely
manner all reports and other documents required of the Company under the
Securities Act and the Exchange Act.

         11.      AMENDMENT OF REGISTRATION RIGHTS. Any provision of this
Agreement may be amended and the observance thereof may be waived (either
generally or in a particular instance and either retroactively or
prospectively), only with the written consent of the Company and the written
consent of each Holder affected thereby. Any amendment or waiver effected in
accordance with this paragraph shall be binding upon each Holder, each future
Holder, and the Company.

         12.      NOTICES. All notices required or permitted under this
Agreement shall be made in writing signed by the party making the same, shall
specify the section under this Agreement pursuant to which it is given, and
shall be addressed if to (i) the Company at: thehealthchannel.com; Attn: Donald
Shea, CEO; 260 Newport Center Drive, Suite 250, Newport Beach, CA 92660;
Telephone: (949) 631-8317, Facsimile: (949) 719-6055, last address as the party
as shown on the records of the Company. Any notice, except as otherwise provided
in this Agreement, shall be made by fax and shall be deemed given at the time of
transmission of the fax.

         13.      TERMINATION. This Agreement shall terminate on the date all
Registrable Securities cease to exist (as that term is defined in Section 2.1
hereof); but without prejudice to (i) the parties' rights and obligations
arising from breaches of this Agreement occurring prior to such termination (ii)
other indemnification obligations under this Agreement.

         14.      ASSIGNMENT. No assignment, transfer or delegation, whether by
operation of law or otherwise, of any rights or obligations under this Agreement
by the Company or any Holder, respectively, shall be made without the prior
written consent of the majority in interest of the Holders or the Company,
respectively; provided that the rights of a Holder may be transferred to a
subsequent holder of the Holder's Registrable Securities (provided such
transferee shall provide to the Company, together with or prior to such
transferee's request to have such Registrable Securities included in a
Registration, a writing executed by such transferee agreeing to be bound as a
Holder by the terms of this Agreement), and the Company hereby agrees to file an
amended registration statement including such transferee or a selling security
holder thereunder; and provided further that the Company may transfer its rights
and obligations under this Agreement to a purchaser of all or a substantial
portion of its business if the obligations of the Company under this Agreement
are assumed in connection with such transfer, either by merger or other
operation of law (which may include without limitation a transaction whereby the
Registrable Securities are converted into securities of the successor in
interest) or by specific assumption executed by the transferee.

         15.      GOVERNING LAW. This Agreement shall be governed by and
construed in accordance with the laws of the State of Georgia applicable to
agreements made in and wholly to be performed in that jurisdiction, except for
matters arising under the Securities Act or the Exchange Act, which matters
shall be construed and interpreted in accordance with such laws. Any dispute
arising out of or relating to this Agreement or the breach, termination or
validity hereof shall be finally settled by the federal or state courts located
in FULTON COUNTY, GEORGIA.

         16.      EXECUTION IN COUNTERPARTS PERMITTED. This Agreement may be
executed in any number of counterparts, each of which shall be enforceable
against the parties actually executing such counterparts, and all of which
together shall constitute one (1) instrument.

<PAGE>

         17.      SPECIFIC PERFORMANCE. The Holder shall be entitled to the
remedy of specific performance in the event of the Company's breach of this
Agreement, the parties agreeing that a remedy at law would be inadequate.

         18.      INDEMNITY. Each party shall indemnify each other party against
any and all claims, damages (including reasonable attorney's fees), and expenses
arising out of the first party's breach of any of the terms of this Agreement.

         19.      ENTIRE AGREEMENT; WRITTEN AMENDMENTS REQUIRED. This Agreement,
including the Exhibits attached hereto, the Investment Agreement, the Common
Stock certificates, and the other documents delivered pursuant hereto constitute
the full and entire understanding and agreement between the parties with regard
to the subjects hereof and thereof, and no party shall be liable or bound to any
other party in any manner by any warranties, representations or covenants except
as specifically set forth herein or therein. Except as expressly provided
herein,

                           [INTENTIONALLY LEFT BLANK]

<PAGE>

neither this Agreement nor any term hereof may be amended, waived, discharged or
terminated other than by a written instrument signed by the party against whom
enforcement of any such amendment, waiver, discharge or termination is sought.

         IN WITNESS WHEREOF, the undersigned have executed this Agreement as of
this 15th day of August, 2000.

                           THE HEALTHCHANNEL.COM

                          By: /s/ DONALD SHEA
                              ---------------------------------------
                                   Donald Shea, CEO

                 Address:          260 Newport Center Drive,
                                   Suite 250
                                   Newport Beach, CA  92660
                                   Telephone: (949) 631-8317
                                   Facsimile:  (949) 719-6055

                             SUBSCRIBER:
                             SWARTZ PRIVATE EQUITY, LLC

                           By:  ERIC S. SWARTZ
                              ---------------------------------------
                                   Eric S. Swartz, Manager

                  Address:         1080 Holcomb Bridge Road
                                   Bldg. 200, Suite 285
                                   Roswell, GA  30076
                                   Telephone: (770) 640-8130
                                   Facsimile:  (770) 640-7150

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00014-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00014-of-00352.parquet"}]]